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1. Introduction 
 
Breast cancer is the most common malignancy among females and the fifth most common 
cause of cancer death worldwide which comprises about 10.4% of all cancers [1]. To be detected, a 
breast tumor should be at least a few millimeters in size. Only 60 percent of breast cancer is 
diagnosed at a local stage. At the time of primary diagnosis, usually tumor cells have already been 
shed and metastases had already occurred [2].  
Localized breast cancer at an early stage has better prognosis and requires less severe treatment 
with a survival rate of 98% [3], however, diagnosis after tumor metastasis has lower survival rate to 
27% [4]. This highlights the importance of early breast cancer detection which is dependent on 
sensitive and specific screening methods. The traditional triple test for breast cancer diagnosis 
includes physical examination, mammography and aspiration cytology. Unfortunately, all these 
methods are not sensitive enough in identifying breast cancer in early stages [3,5]. A minimally 
invasive screening test beside the triple test, or prior to biopsy, would lead to greater sensitivity. 
Many researchers have attempted to establish molecular and immunological methods for the 
detection of individual metastatic breast cancer cells in peripheral blood [6] but still finding an 
accurate and sensitive biomarker remains challenging [7]. 
The increasing knowledge about the various forms of cancer, especially for the breast cancer, 
including genetic, molecular and cellular mechanisms, is now providing clear objectives for their 
early detection, prevention, and therapy. The past 10 years have shown impressive progress in the 
field of large scale and high-throughput biology, resulting in a new area of technology development 
and improve of knowledge. During these years, protein- and nucleic acid -based high-throughput 
analyses have identified a substantial number of markers at the levels of proteins, genes, and gene 
expression, which can be linked to various forms of cancer.  
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Recently, the epigenetic of human cancer have become more visible due to increasing 
understanding of specific epigenetic mechanisms, including hypomethylation, hypermethylation, 
loss of imprinting, and chromatin modification [8]. It is becoming more evident that epigenetic, as 
well as genetic events might have important role in the initiation and progression of cancer. 
Hypermethylation of gene-promoter regions is being revealed as a loss of gene function, which is 
frequently found in cancers [9].  
Hypermethylation of human tumor suppressor genes (TSGs) leads to the silencing of genes 
responsible for tumor suppression, thus causing cancers. Aberrant DNA methylation patterns have 
been suggested as biomarkers in cancer molecular diagnostics [10]. Methylation is the ideal 
parameter for comprehensive diagnostics in cancer management, with the potential to trigger a 
change in paradigm from single to multiple markers, and from individuals to a disease-management 
approach [11]. Recent technology development has provided the analysis of DNA methylation in a 
genome-wide scale [12,13] which may not be easily accessible for many institutions. Thereby, in 
most of the research centres methylation assays can be only determined on gene-by-gene analysis. 
Additionally clinical usefulness of methylation is still limited due to the fact that none of the 
available techniques are broadly accurate for quantification and sensitive detection of methylation 
changes in cancers [9]. Large-scale studies that enable evaluating quantitative alterations of 
methylation for multiple CpG sites in various gene regions and testing a large number of samples 
with automation are rare [9,14]. 
The use of methylation changes as a biomarker has a number of advantages compared with 
other approaches. Two of these advantages should be underlined: First, there is strong evidence that 
methylation is an early event in carcinogenesis, a characteristic highly desired in cancer biomarkers. 
Second, the DNA containing the methylation information is highly stable and can be easily isolated 
from most body fluids, as well as from archived fixed tissues. These include early detection, 
chemoprevention, and disease monitoring [15]. 
It is well recognized that solid malignant tumors release significant amounts of DNA into the 
systemic circulation through cellular necrosis or apoptosis [16]. The presence of cell-free DNA 
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(cfDNA) in plasma and serum has been known for over 60 years. Quantitative alteration of 
circulating cfDNA has been observed in several cancers including breast cancer [17]. The tumor 
released DNA in circulation might serve as biomarker for cancer [17]. Tumor-specific methylated 
DNA alterations have been found in the circulation of patients with different types of cancer 
[18,19]. The analysis of the methylation patterns of cfDNA by a blood-based test might enable to 
distinguish between benign and malignant tumors for diagnosis and surveillance of patients [19]. 
Abnormalities in non-coding genes can also contribute to cancer pathogenesis [20,21]. 
MicroRNAs (miRNAs) are endogenous non-coding RNAs with 19-25 nucleotides in size that 
deregulation of them contribute to cancer development and progression [22]. Recent evidence 
indicates that some miRNAs can function either as oncogenes or tumor suppressors [21,23], and 
expression profiling analyses have revealed characteristic miRNA signatures in certain human 
cancers [20,24]. However, the precise parts played by the expressed miRNAs in specific steps of 
malignant progression, including metastasis, are still unknown. Moreover, emerging studies 
reported that miRNAs are involved in promoter DNA methylation changes [25]. However, DNA 
sequences encoding miRNAs were found to be a target of aberrant DNA methylation as well as 
protein-coding genes [26]. 
Methylation causes the inactivation of numerous genes/miRNAs that are important in the 
development of most, or all, tumor types. Genetic changes such as mutation or deletion resulting 
permanent loss of gene expression whereas epigenetic changes such as DNA methylation can be 
pharmacologically reversible and could be a useful target to develop new therapeutic strategies for 
cancer therapy [27,28]. Reversal hypermethylation of silenced TSGs or miRNAs is increasingly 
being targeted for cancer therapy and prevention strategies [29,30]. Moreover, These approaches 
are particularly appealing because of the less toxicity of DNA methylation inhibitors in non-
cancerous tissues than the other anti-cancer drugs [15]. 
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2. Aim of the study 
 
Method development approaches 
I) The rapidly expanding interest in the involvement of DNA methylation in developmental 
mechanisms, human diseases and malignancies has highlighted the need for an accurate, 
quantitative and high-throughput assay. Existing methods are limited, and are often too laborious 
for high throughput or inadequate for quantitative analysis of methylation. Therefore, the primary 
aim of this thesis was to present an approach that allows for reduced costs, based on the 
SEQUENOM’s EpiTYPER™  which is a high-throughput methylation quantification method and 
relies on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF 
MS) and our modified protocol.  
II) Investigation of DNA, RNA and proteins for downstream genetic, epigenetic, transcriptomic 
and proteomic analysis holds an important place in the field of medical care and life science. This is 
often hampered by the limited availability of sample material.  Therefore an increasing interest rises 
for simultaneous isolation of DNA, RNA and proteins from a single sample aliquot. As another aim 
we tried to establish applicable methodology of simultaneous isolation of DNA, RNA and/or 
proteins for quantitative and qualitative analysis of breast cancerous cell lines, whole blood, buffy 
coat, serum, plasma and formalin-fixed paraffin-embedded tissues for genetic, epigenetic, 
transcriptomic and proteomic profiling. 
 
Biomarker discovery in cancerous and paired normal breast tissues 
Alterations of DNA methylation patterns have been suggested as biomarkers for diagnosis and 
therapy of cancers. Every novel discovery in the epigenetic landscape and every development of an 
improved approach for accurate analysis of the events may offer new opportunity for the 
management of patients. Breast cancer is the most common type of cancer and most common 
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leading cause of cancer death in women. Therefore, the main aim of this study was to focus on the 
careful selection and analyses of candidate genes mainly involved in breast cancer pathways. In this 
study, we investigated quantitative methylation changes of 22 human genes (APC, BIN1, BMP6, 
BRCA1, BRCA2, CADHERIN 1, CST6, DAPK1, EGFR, ESR2, GSTP1, NES1, Nm23-H1, P16, P21, 
Progesterone receptor, Prostasin, RAR-b, RASSF1, SRBC, TIMP3, TP53) in the breast cancer tissue 
compared to the paired normal tissue using MALDI-TOF MS system purposing novel applicable 
biomarkers for diagnosis and prognosis of patients. The selected candidate cancer genes for this 
study have annotated functionality in the cell adhesion, cell interaction, invasion, metastasis, 
angiogenesis or gene expression during cancer development and progression. In order to understand 
the relationship between methylation and transcription events, individual assessment of the 
methylation status of each CpG dinucleotide was performed to check the position of 
hypermethylated sites along the gene’s promoter.  
Unregulated cell growth, a major hallmark of cancer, is associated with telomere shortening. 
Measurement of telomere length could provide important information on cell replication and 
proliferation status in cancer tissues. In another part of study we investigated a potential link 
between promoter hypermethylation of the TP53, P21 and P16 genes and telomere length 
shortening in the paired breast tumor and the adjacent normal breast tissue by quantitative PCR and 
MALDI-TOF MS to measure relative telomere length and promoter methylation level of 
aforementioned genes, respectively. Additionally, we compared telomere length in tumor tissues to 
traditional pathological parameters and clinical predictive markers. 
 
Non-invasive biomarker discovery based on cancer specific methylation 
alteration 
It is well recognized that solid malignant tumors release significant amounts of DNA into the 
systemic circulation through cellular necrosis or apoptosis. Quantitative alterations of circulating 
cell-free DNA have been observed in several cancers. This tumor-released DNA in blood might 
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serve as biomarker for cancer. In the present study, to achieve a reliable gene panel for developing a 
high-throughput blood-based test, we quantitatively assessed the DNA methylation profile of 10 
breast cancer candidate genes (APC, BIN1, BMP6, BRCA1, CST6, ESR2, GSTP1, P16, P21 and 
TIMP3) using MALDI-TOF MS in two different cohorts of patients with breast cancer on large-
scale CpG sites.  
Demethylation treatment  
Genetic changes such as mutation or deletion resulting permanent loss of gene expression 
whereas epigenetic changes can be pharmacologically reversible and might be a useful target to 
develop new therapeutic strategies for cancer therapy. Reversal hypermethylation of silenced tumor 
suppressor genes or miRNAs is increasingly being targeted for cancer therapy and prevention 
strategies.   
The 5-aza-2′-deoxycytidine (decitabine; DAC; Dacogen, Eisai, Inc.) as an effective 
demethylation drug is recently approved by the Food and Drug Administration (FDA) for the 
treatment of patients with Myelodysplastic Syndromes (MDS) and leukemia. The DAC is a 
nucleotide analog that is activated via phosphorylation by cellular deoxcytidine kinase and 
incorporated into the DNA at S phase, eventually lead to depletion of methyltransferase activity and 
demethylation of DNA.   
Present study investigated the therapeutic value of DAC on the cancer specific hypermethylated 
genes. We could also provide a multidimensional model which showed complete early and late 
effects of DAC at the level of the genome, epigenome and proteome for subtypes of breast cancer. 
The present study initially assessed effective dosage of DAC for breast cancer therapy based on 
promoter demethylation considering cell viability, cytotoxicity and apoptosis for six breast cancer 
cell lines and a breast epithelial cell line as control. Then two breast cancer subtypes including 
highly aggressive and non-aggressive cell lines as well as the control cell line were investigated in 
more detail using 3-dimentional omics (gene expression, microRNA expression and proteomics 
analysis).  
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3. Published review article: 
 
New trends in molecular biomarker discovery for breast cancer 
 
 
Journal: Genet Test Mol Biomarkers. 2009 Oct;13(5):565-71. Review. 
 
 
Summary:  
Breast cancer is one of the most common leading causes of cancer death in women and early 
diagnosis, selection of appropriate therapeutic strategies and efficient follow up play an important 
role in reducing mortalities. Our review highlights the new trends and approaches in breast cancer 
biomarker discovery, which could be used for early diagnosis, development of new therapeutic 
approaches and follow up of patients. 
 
 
First author’s contribution:  
Ramin Radpour was involved in writing the manuscript.  
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4. Published research article: 
 
High-throughput hacking the methylation patterns in breast cancer by  
in vitro transcription and thymidine-specific cleavage mass array on  
MALDI-TOF silico-chip 
 
Journal: Mol Cancer Res. 2008 Nov;6(11):1702-9. 
 
 
Summary:  
DNA methylation is an important potential biomarker in cancer study but still an accurate, 
sensitive and reproducible high-throughput quantification of DNA methylation with compatibility 
of automation remains challenging. To find an efficient and more cost effective high-throughput 
method for analyzing the methylation profile in breast cancer, we assessed a methodological 
approach that allows for the simultaneous detection of multiple target CpGs residue and quantifies 
up to 5% of methylated sequence in unmethylated background by employing thymidine-specific 
cleavage mass array on MALDI-TOF slico chips. We evaluated the accuracy, variability and 
sensitivity of the approach, and implemented critical improvements in experimental design. 
 
 
 
First author’s contribution:  
Ramin Radpour was involved in performing the experiment and data analysis.  
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5. Published research article: 
 
Simultaneous isolation of DNA, RNA and proteins for genetic, epigenetic, 
transcriptomic and proteomic analysis 
 
Journal: J Proteome Res. 2009 Nov;8(11):5264-74. 
 
 
Summary:  
Analysis of DNA, RNA and proteins for downstream genetic, epigenetic, transcriptomic and 
proteomic analysis is often hampered by the limited availability of sample material. We present a 
methodological approach using the Qiagen AllPrep method that allows efficient isolation and 
purification of DNA, RNA and proteins from a single sample aliquot of cell lines, whole blood, 
buffy coat, serum, plasma and formalin-fixed paraffin-embedded tissues. The efficiency, quality, 
quantity and purity of the samples obtained by this strategy were confirmed by several genetic, 
epigenetic, transcriptomic and proteomic methods. This approach, when compared to the 
procedures based on separate extraction of samples, is convenient both in terms of its simplicity and 
cost-effectiveness. 
 
 
First author s’ contribution:  
Ramin Radpour was involved in study design, making collaborations, data analysis and writing the 
manuscript.  
Michal Sikora was involved in performing the experiment and data analysis. 
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Supplementary Data 1 
 
 
Table 1. The sequence of PCR primers for Real-time PCR  
Gene Primer Sequence (5’→3’) Length Ta Prodoct Size (bp) 
GAPDH (for DNA) 
Forward CCCCACACACATGCACTTACC 21 
60 97 Reverse CCTAGTCCCAGGGCTTTGATT 20 
Probe MGB–TAGGAAGGACAGGCAAC–FAM 17
GAPDH (for RNA) Forward GAAGGTGAAGGTCGGAGT 18 60 226 Reverse GAAGATGGTGATGGGATTTC 20 
 
For the quantitative PCR (Q-PCR) of DNA, we used a reaction volume of 25L, containing 5L of 
template, primers at a concentration of 300nM, a probe at 200nM, and 12,5L of 2xTaqMan 
Master Mix (Applied Biosystems, Branchburg, New Jersey, USA). The reaction was performed at 
the following conditions: a first denaturation step at 95C for 10 minutes, and 40 cycles of 1 minute 
at 60C, followed by 15 seconds at 95C. For the Q-PCR of RNA samples, an aliquot of 25ng (5μL) 
template cDNA was added to each reaction containing 12.5μL SYBR, Green PCR Master Mix 
(Applied Biosystems, Foster City, California, USA) and 7.5μL primers mixture. The thermal 
cycling profile for the GAPDH was 95oC for 10 min, followed by 40 cycles of 95oC for 15s and 
60oC for 1min. Following amplification of GAPDH in cDNA samples, a dissociation curve was 
drawn in order to confirm the specificity of the reaction. 
 
 
 
Table 2. The sequence of PCR tagged primers for in vitro transcription and quantitative methylation 
study  
Gene Primer Sequence (5’→3’) Length Ta Product Size (bp) 
BIN1 tag-EN1-FW 
AGGAAGAGAGGGAGGTGAGTTTTTGGAA 18+10 58 330 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCTACCTTTTAAAAAACCACTCC 22+31 
P16 
(CDKN2A) 
tag-EN1-FW AGGAAGAGAGGGTTGTTTTTGGTAGGG 17+10 58 580 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTATATAAACCACRAAAACCC 19+31 
RAR-b tag-EN1-FW 
AGGAAGAGAGGAGTGTATGTTAATGGGGGAG 21+10 56 475 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTTTCCCAACATAATTTCTCTAC 21+31 
RASSF1 tag-EN1-FW 
AGGAAGAGAGGGGYGGTAAAGTTGTTGA 18+10 56 346 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCRCAATAAAAACCTAAATACA 21+31 
 
For the PCR on bisulphite-treated genomic DNA (gDNA), the following PCR conditions were 
used: 1x: 95°C for 10 min; 48x: 95°C for 20s, Ta for 30s, 72°C for 1 min; 1x 72°C for 5 min. For 
the PCR on gDNA, the following cycling conditions were used: 1x: 95°C for 10 min; 40x: 95°C for 
20 s, Ta for 30s, 72°C for 45s; 1x 72°C for 5 min. After first round of PCR amplification we used 
1µl of the PCR product for re-amplification of selected amplicons with the same primer pairs. 
 
 
 
Primer taging for in vitro transcription. (A) Reverse primer with T7-promoter tag. (B) Forward 
primer with 10mer tag sequence as balance. 
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Supplementary Data 2 
 
Qualitative determination of extracted DNA using high-throughput methylation analysis of 
four tumor suppressor genes by thymidine-specific cleavage mass array on MALDI-TOF 
silico-chip, before and after re-amplification 
 
 
 
Colored circles representing analyzed CpG sites (Red color indicates 0% methylated, yellow color indicates 100% 
methylated and color gradient between red and yellow indicates methylation ranging from 0-100) and open circles 
representing not analyzed CpG sites. 
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The effect of re-amplification on high-throughput methylation analysis of four studied tumor 
suppressor genes using MALDI-TOF MS (* significant correlation; Mann-Whitney U Test).  
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Supplementary Data 3 
 
 
Two-dimensional (2D) gel electrophoresis for SKBR3 breast cancer cell line  
 
 
 
 
Assessment of protein extraction efficiency and quality using the two-dimensional (2D) gel 
electrophoresis for SKBR3 breast cancer cell line. Circles were used to define regions where 
differences could be observed between proteins extracted using traditional normal method in 
comparison with AllPrep method. 
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6. Published research article: 
 
Methylation profiles of 22 candidate genes in breast cancer using high-
throughput MALDI-TOF mass array 
 
Journal: Oncogene. 2009 Aug 20;28(33):2969-78. 
 
 
Summary:  
For the first time, we used a high-throughput mass array to quantify the methylation status of 
22 genes in breast cancer. We quantitatively analyzed 42,528 CpG sites on the genes in paired 
cancerous and adjacent normal breast tissues (96 samples) from 48 patients with breast cancer. 
Using the hierarchical clustering and distance analysis, 10 hypermethylated genes (APC, BIN1, 
BMP6, BRCA1, CST6, ESRb, GSTP1, P16, P21 and TIMP3) were identified for breast cancer. The 
breast cancer tissue specific hypermethylated genes identified in this study might provide valuable 
information in their application for the classification, sensitive detection, risk and therapy 
assessment of breast cancer, as well as for developing novel targeted therapeutic strategies via 
modification of pathological epigenetic changes in cancer. 
 
 
First author’s contribution:  
Ramin Radpour was involved in performing the experiment, data analysis and writing the 
manuscript.  
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Supplementary Data 1 
 
The sequence of PCR tagged primers for in vitro transcription and PCR conditions 
 
For the PCR on bisulphite-treated genomic DNA (gDNA), the following PCR conditions were 
used: 1x: 95°C for 10 min; 48x: 95°C for 20s, Ta for 30s, 72°C for 1 min; 1x 72°C for 5 min. For 
the PCR on gDNA, the following cycling conditions were used: 1x: 95°C for 10 min; 40x: 95°C for 
20 s, Ta for 30s, 72°C for 45s; 1x 72°C for 5 min. After first round of PCR amplification we used 
1.5µl of the PCR product for re-amplification of selected amplicons with the same primer pairs. 
 
 
Gene Primer Sequence (5’→3’) Length Ta 
Prodoct 
Size 
(bp) 
APC tag-EN1-FW 
AGGAAGAGAGATTGTTTTTTTGTGTTGTAAAAATTAT 27+10 58 420 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCACCTCCATTCTATCTCCAATAAC 24+31 
BIN1 tag-EN1-FW 
AGGAAGAGAGGGAGGTGAGTTTTTGGAA 18+10 58 330 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCTACCTTTTAAAAAACCACTCC 22+31 
BMP6 tag-EN1-FW 
AGGAAGAGAGGGGGTAAATTTTATGGTGGTTT 22+10 57 397 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCCTTCCTAACCCTCAATCCTTA 22+31 
BRCA1 tag-EN1-FW 
AGGAAGAGAGAATTGGAGATTTTTATTAGG 20+10 56 413 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTAAATCTCAACRAACTCAC 18+31 
BRCA2 tag-EN1-FW 
AGGAAGAGAGTTGGGATGTTTGATAAGGAATTT 23+10 61 433 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTAAACAAAAAAACAAAAAACCRC 22+31 
CADHERIN 1  tag-EN1-FW 
AGGAAGAGAGGGTGAAAGAGTGAGATTTTATTTTTA 26+10 57 500 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCTCCAAAAACCCATAACTAACC 22+31 
CST6 tag-EN1-FW 
AGGAAGAGAGGTTGGTAGTTTATTTTGGATAGTTT 25+10 59 445 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCAAATCCCRAAATTCTCC 18+31 
DAPK1 tag-EN1-FW 
AGGAAGAGAGTTTGTAATTTTAGTATTTTGGGAGG 25+10 56 408 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTAAATACACATTAAAATCCAAAACAA 25+31 
EGFR tag-EN1-FW 
AGGAAGAGAGTYGATTTGGATATAGGTTGGG 21+10 62 428 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCCRAAACTAACTCRAAACTCC 21+31 
ESR2 (ER 
beta) 
tag-EN1-FW AGGAAGAGAGTTTAGTTGTTGGTTTTTTGGAT 22+10 58 374 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTAAAATTTCAAACAAAATAAAACAATT 26+31 
GSTP1 tag-EN1-FW 
AGGAAGAGAGTTYGGGAGGTTGAAGTAGA 19+10 60 381 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTAAACAAACAACAAAAAAAAAACC 23+31 
NES1 
(Island 1) 
tag-EN1-FW AGGAAGAGAGATATAGATGGTAGGGAGGGTG 21+10 56 546 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTATACAAACTTCTCCCAATACCC 22+31 
NES1 
(Island 2) 
tag-EN1-FW AGGAAGAGAGGTTAGGGGTTTTTGGGTAGAG 21+10 61 410 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTAACACAATTACCCTAATAACRCC 23+31 
Nm23-H1 
(NME1) 
tag-EN1-FW AGGAAGAGAGTAGGTATTTAAAATTTTTTGTTTGA 25+10 57 421 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTATTTAAACTCCRACTACAACC 21+31 
P16 
(CDKN2A) 
tag-EN1-FW AGGAAGAGAGGGTTGTTTTTGGTAGGG 17+10 58 580 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTATATAAACCACRAAAACCC 19+31 
P21 
(CDKN1A) 
tag-EN1-FW AGGAAGAGAGGGTAAATTTTTGTTTGTTAGAGTGG 25+10 60 419 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTTAACTTCRACAACTACTCACACCT 24+31 
Progesterone 
receptor (PGR) 
tag-EN1-FW AGGAAGAGAGTTYGTTTTAAAGATAAAGGAGGAG 24+10 61 448 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCCTTAAACACRACRACCTAATAACC 25+31 
Prostasin 
(PRSS8) 
tag-EN1-FW AGGAAGAGAGGGGGTATAATTGGTTTGAGATA 22+10 57 450 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTTCCTCCCAAAAATAACTACACCT 23+31 
RAR-b tag-EN1-FW 
AGGAAGAGAGGAGTGTATGTTAATGGGGGAG 21+10 56 475 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTTTCCCAACATAATTTCTCTAC 21+31 
RASSF1 tag-EN1-FW 
AGGAAGAGAGGGGYGGTAAAGTTGTTGA 18+10 56 346 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCRCAATAAAAACCTAAATACA 21+31 
SRBC 
(PRKCDBP) 
tag-EN1-FW AGGAAGAGAGTTTTTGTAGTGGAGAATTGAAATAGG 26+10 57 435 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCAACATAAAAACCAACTTCTCCAAC 25+31 
TIMP3 tag-EN1-FW 
AGGAAGAGAGTTTTGTTATTGGTTTGAGGG 20+10 59 441 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCCAAACTCCAACTACCCA 18+31 
TP53 tag-EN1-FW 
AGGAAGAGAGATGGTTTYGAAGTTTTTAGGGAT 23+10 59 449 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTAATACAAAACCTACTACRCCCTCT 24+31 
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Supplementary Data 2 
High-throughput methylation analysis of informative CpG sites in 22 genes related to breast cancer. 
 
 
 
Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
324 adenomatous polyposis coli 5q21-q22 
Cell adhesion, signal transduction, 
stabilization of the cytoskeleton, regulation 
of cell cycle and apoptosis 
direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
APC gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
274 Bridging integrator 1 2q14 
Encodes several isoforms of a nucleocytoplasmic 
adaptor protein, one of which was initially 
identified as a MYC-interacting protein with 
features of a tumor suppressor. 
direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
BIN1 gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
654 bone morphogenetic protein 6 6p24-p23 
The bone morphogenetic proteins (BMPs) 
are a family of secreted signaling molecules. direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
BMP6 gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
672 Breast Cancer type 1 17q21 
Involved in DNA repair, recombination, 
checkpoint control of the cell cycle and 
transcription. Interacts with p53, STAT-
factors, SRBC, etc. 
direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
BRCA1 gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
675 breast cancer type 2 13q12.3 
Involved in DNA repair, recombination, 
checkpoint control of the cell cycle and 
transcription. 
direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
BRCA2 gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
999 cadherin 1, type 1, E-cadherin 16q22.1 
The encoded protein is a calcium dependent 
cell-cell adhesion glycoprotein. Loss of 
function is thought to contribute to 
progression in cancer by increasing 
proliferation, invasion, and/or metastasis. 
direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
CADHERIN1 (CDH1) gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
1474 Cystatin E/M 11q13 
This gene encodes a cystatin from type 2 family, 
which is down-regulated in metastatic breast tumor 
cells as compared to primary tumor cells. Loss of 
expression is likely associated with the progression of 
a primary tumor to a metastatic phenotype. 
direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues. 
CST6 gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
1612 Death-associated protein kinase 1 9q34.1 
Mediator of interferon-γ induced apoptosis 
and it is a tumor suppressor candidate. direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
DAPK1 gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
1956 epidermal growth factor receptor 7p12 
Receptor for epidermal growth factor and 
erythroblastic leukemia viral (v-erb-b) 
oncogene homolog 
direct 
 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
EGFR gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
2100 estrogen receptor 2 (ER beta) 14q23.2 
Regulation of cell proliferation, predictor of 
endocrine therapy direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
ESR-b gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
2950 Glutathione S-transferase P1 11q13 
Carcinogen detoxification. GSTP1 is a polymorphic 
gene encoding active, functionally different GSTP1 
variant proteins that are thought to function in 
xenobiotic metabolism and play a role in 
susceptibility to cancer, and other diseases. 
direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
GSTP1 gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
5655 Kallikrein-related peptidase 10 
19q13.3-
q13.4 
Inhibition of anchorage-independent growth 
and tumor formation. direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
NES1 (KLK10) gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
4830 non-metastatic cells 1 17q21.3 Metastasis suppressor activity.  direct 
 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
NM23-H1 (NME1) gene
74 Radpour et al. Research Article 
 
 
 
 
Gene ID Alternate gene name locus Function Methylation effect on breast cancer 
1029 
Cyclin-dependent kinase 
inhibitor 2A (melanoma, 
p16, inhibits CDK4) 
9p21 Cell cycle regulation, involved in senescence. direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
P16 (CDKN2A) gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
1026 
Cyclin-dependent 
kinase inhibitor 
1A (p21, Cip1) 
6p21.2 
Encodes protein that binds to and inhibits the 
activity of cyclin-CDK2 or -CDK4 complexes, 
and thus functions as a regulator of cell cycle 
progression at G1. This protein plays a regulatory 
role in S phase DNA replication and DNA 
damage repair. 
direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
P21 (CDKN1A) gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
5241 Progesterone receptor 11q22-q23 
This gene encodes a member of the steroid 
receptor superfamily. Altered expression of this 
gene has been associated with the pathogenesis 
of breast cancers 
direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
Progesterone Receptor (PGR) gene 
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
5652 Protease serine 8 16p11.2 Suppression of invasion. direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
Prostasin (PRSS8) gene 
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
5915 Retinoic acid receptor β 3p24 
Apoptosis, involved in senescence, inhibition of 
proliferation direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
RAR-b gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
11186 
Ras association 
(RalGDS/AF-6) 
domain family 1 
3p21.3 
This gene encodes a protein similar to the RAS 
effector proteins. Loss or altered expression of 
this gene has been associated with the 
pathogenesis of a variety of cancers, which 
suggests the tumor suppressor function of this 
gene. 
direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
RASSF1 gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
112464 
protein kinase C, 
delta binding 
protein 
11p15.4 
Interaction with BRCA1. The expression of this 
protein was found to be down-regulated in various 
cancer cell lines, suggesting the possible tumor 
suppressor function of this protein. 
direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
SRBC (PRKCDBP) gene
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Gene ID Alternate gene name locus Function 
Methylation effect 
on breast cancer 
7078 Tissue inhibitor of metalloproteinase-3 22q12.3 
Suppresses tumor growth, angiogenesis, 
invasion and metastasis direct 
 
 
Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.  
 
TIMP3 gene
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Gene ID Alternate gene name locus Function 
Methylation 
effect on breast 
cancer 
7157 Transformation-related protein 53 17p13.1 
Apoptosis, cell cycle regulation, inhibition of 
growth and invasion. direct 
 
 
 Two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 adjacent normal tissues.
TP53 gene
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7. Published research article: 
 
Hypermethylation of tumor suppressor genes involved in critical 
regulatory pathways for developing a high-throughput blood-based test in 
breast cancer 
 
 
Journal: PLoS One. 2011 Jan 24;6(1):e16080. 
 
 
Summary:  
In this study, the methylation profile of 10 tumor suppressor genes (APC, BIN1, BMP6, 
BRCA1, CST6, ESR-b, GSTP1, P16, P21 and TIMP3) involved in critical cellular and molecular 
regulatory pathways were quantitatively assessed using a mass spectrometry on MALDI-TOF MS 
in circulating cell-free DNA, paired breast tumor and normal tissue of different 126 samples. The 
possibility of using the cancer specific alterations in plasma and serum samples as an epigenetic 
blood-based test for breast cancer was explored. Our study on clinical samples suggests that the 
selected TSG panel combined with the high-throughput technology is a useful tool to develop 
epigenetic based biomarker for breast cancer relies on pathologic methylation changes in tumor 
tissue, as well as in circulation. 
 
 
First author’s contribution: 
Ramin Radpour was involved in performing the experiment, data analysis and writing the 
manuscript. 
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Dataset S1 
High-throughput methylation analysis of CpG sites in 10 candidate genes related to breast cancer. 
 
 
 
 
 
Double dendrogram of APC gene: Two-way hierarchical cluster analysis of 36 plasma samples 
from breast cancer patients and 30 plasma samples of normal subjects. (Red clusters indicate 0% 
methylated, yellow clusters indicate 100% methylated, color gradient between red and yellow 
indicates methylation ranging from 0-100, and black clusters indicate not analyzed CpG sites). 
 
 
Double dendrogram of APC gene: Two-way hierarchical cluster analysis of 60 triple samples 
(breast cancerous tissue, matched normal tissue serum and samples) from 20 breast cancer patients. 
(Red clusters indicate 0% methylated, yellow clusters indicate 100% methylated, color gradient 
between red and yellow indicates methylation ranging from 0-100, and black clusters indicate not 
analyzed CpGs). 
APC Gene
96 Radpour et al. Research Article 
 
 
 
 
 
 
Double dendrogram of BIN1 gene: Two-way hierarchical cluster analysis of 36 plasma samples 
from breast cancer patients and 30 plasma samples of normal subjects. (Red clusters indicate 0% 
methylated, yellow clusters indicate 100% methylated, color gradient between red and yellow 
indicates methylation ranging from 0-100, and black clusters indicate not analyzed CpG sites). 
 
 
Double dendrogram of BIN1 gene: Two-way hierarchical cluster analysis of 60 triple samples 
(breast cancerous tissue, matched normal tissue serum and samples) from 20 breast cancer patients. 
(Red clusters indicate 0% methylated, yellow clusters indicate 100% methylated, color gradient 
between red and yellow indicates methylation ranging from 0-100, and black clusters indicate not 
analyzed CpGs). 
 
BIN1 Gene
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\ 
 
Double dendrogram of BMP6 gene: Two-way hierarchical cluster analysis of 36 plasma samples 
from breast cancer patients and 30 plasma samples of normal subjects. (Red clusters indicate 0% 
methylated, yellow clusters indicate 100% methylated, color gradient between red and yellow 
indicates methylation ranging from 0-100, and black clusters indicate not analyzed CpG sites). 
 
 
Double dendrogram of BMP6 gene: Two-way hierarchical cluster analysis of 60 triple samples 
(breast cancerous tissue, matched normal tissue serum and samples) from 20 breast cancer patients. 
(Red clusters indicate 0% methylated, yellow clusters indicate 100% methylated, color gradient 
between red and yellow indicates methylation ranging from 0-100, and black clusters indicate not 
analyzed CpGs). 
BMP6 Gene
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Double dendrogram of BRCA1 gene: Two-way hierarchical cluster analysis of 36 plasma samples 
from breast cancer patients and 30 plasma samples of normal subjects. (Red clusters indicate 0% 
methylated, yellow clusters indicate 100% methylated, color gradient between red and yellow 
indicates methylation ranging from 0-100, and black clusters indicate not analyzed CpG sites). 
 
 
Double dendrogram of BRCA1 gene: Two-way hierarchical cluster analysis of 60 triple samples 
(breast cancerous tissue, matched normal tissue serum and samples) from 20 breast cancer patients. 
(Red clusters indicate 0% methylated, yellow clusters indicate 100% methylated, color gradient 
between red and yellow indicates methylation ranging from 0-100, and black clusters indicate not 
analyzed CpGs). 
 
BRCA1 Gene
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Double dendrogram of CST6 gene: Two-way hierarchical cluster analysis of 36 plasma samples 
from breast cancer patients and 30 plasma samples of normal subjects. (Red clusters indicate 0% 
methylated, yellow clusters indicate 100% methylated, color gradient between red and yellow 
indicates methylation ranging from 0-100, and black clusters indicate not analyzed CpG sites). 
 
 
Double dendrogram of CST6 gene: Two-way hierarchical cluster analysis of 60 triple samples 
(breast cancerous tissue, matched normal tissue serum and samples) from 20 breast cancer patients. 
(Red clusters indicate 0% methylated, yellow clusters indicate 100% methylated, color gradient 
between red and yellow indicates methylation ranging from 0-100, and black clusters indicate not 
analyzed CpGs). 
 
CST6 Gene
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Double dendrogram of ESR-b gene: Two-way hierarchical cluster analysis of 36 plasma samples 
from breast cancer patients and 30 plasma samples of normal subjects. (Red clusters indicate 0% 
methylated, yellow clusters indicate 100% methylated, color gradient between red and yellow 
indicates methylation ranging from 0-100, and black clusters indicate not analyzed CpG sites). 
 
 
Double dendrogram of ESR-b gene: Two-way hierarchical cluster analysis of 60 triple samples 
(breast cancerous tissue, matched normal tissue serum and samples) from 20 breast cancer patients. 
(Red clusters indicate 0% methylated, yellow clusters indicate 100% methylated, color gradient 
between red and yellow indicates methylation ranging from 0-100, and black clusters indicate not 
analyzed CpGs). 
ESR-b Gene
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Double dendrogram of GSTP1 gene: Two-way hierarchical cluster analysis of 36 plasma samples 
from breast cancer patients and 30 plasma samples of normal subjects. (Red clusters indicate 0% 
methylated, yellow clusters indicate 100% methylated, color gradient between red and yellow 
indicates methylation ranging from 0-100, and black clusters indicate not analyzed CpG sites). 
 
 
Double dendrogram of GSTP1 gene: Two-way hierarchical cluster analysis of 60 triple samples 
(breast cancerous tissue, matched normal tissue serum and samples) from 20 breast cancer patients. 
(Red clusters indicate 0% methylated, yellow clusters indicate 100% methylated, color gradient 
between red and yellow indicates methylation ranging from 0-100, and black clusters indicate not 
analyzed CpGs). 
 
GSTP1 Gene
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Double dendrogram of P16 gene: Two-way hierarchical cluster analysis of 36 plasma samples 
from breast cancer patients and 30 plasma samples of normal subjects. (Red clusters indicate 0% 
methylated, yellow clusters indicate 100% methylated, color gradient between red and yellow 
indicates methylation ranging from 0-100, and black clusters indicate not analyzed CpG sites). 
 
 
Double dendrogram of P16 gene: Two-way hierarchical cluster analysis of 60 triple samples 
(breast cancerous tissue, matched normal tissue serum and samples) from 20 breast cancer patients. 
(Red clusters indicate 0% methylated, yellow clusters indicate 100% methylated, color gradient 
between red and yellow indicates methylation ranging from 0-100, and black clusters indicate not 
analyzed CpGs). 
P16 (CDKN2A) Gene
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Double dendrogram of P21 gene: Two-way hierarchical cluster analysis of 36 plasma samples 
from breast cancer patients and 30 plasma samples of normal subjects. (Red clusters indicate 0% 
methylated, yellow clusters indicate 100% methylated, color gradient between red and yellow 
indicates methylation ranging from 0-100, and black clusters indicate not analyzed CpG sites). 
 
 
Double dendrogram of P21 gene: Two-way hierarchical cluster analysis of 60 triple samples 
(breast cancerous tissue, matched normal tissue serum and samples) from 20 breast cancer patients. 
(Red clusters indicate 0% methylated, yellow clusters indicate 100% methylated, color gradient 
between red and yellow indicates methylation ranging from 0-100, and black clusters indicate not 
analyzed CpGs). 
 
P21 (CDKN1A) Gene
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Double dendrogram of TIMP3 gene: Two-way hierarchical cluster analysis of 36 plasma samples 
from breast cancer patients and 30 plasma samples of normal subjects. (Red clusters indicate 0% 
methylated, yellow clusters indicate 100% methylated, color gradient between red and yellow 
indicates methylation ranging from 0-100, and black clusters indicate not analyzed CpG sites). 
 
 
Double dendrogram of TIMP3 gene: Two-way hierarchical cluster analysis of 60 triple samples 
(breast cancerous tissue, matched normal tissue serum and samples) from 20 breast cancer patients. 
(Red clusters indicate 0% methylated, yellow clusters indicate 100% methylated, color gradient 
between red and yellow indicates methylation ranging from 0-100, and black clusters indicate not 
analyzed CpGs). 
TIMP3 Gene
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Dataset S2 
 
 
 
Correlation study of the mean methylation proportion of informative CpG sites for ccfDNA in 
serum versus tumor and normal samples (S: Serum, N: Normal, T: Tumor). 
106 Radpour et al. Research Article 
 
 
 
 
 
Correlation study of the mean methylation proportion of informative CpG sites for ccfDNA in 
serum versus tumor and normal samples (S: Serum, N: Normal, T: Tumor).  
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Dataset S3 
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8. Published research article: 
 
Correlation of Telomere Length Shortening with Promoter Methylation 
Profile of p16/Rb and p53/p21 pathways in Breast Cancer 
 
Journal: Mod Pathol. 2010 May;23(5):763-72. 
 
 
Summary:  
In this study, telomere shortening and its potential correlation with down regulation of cell 
cycle regulatory elements were studied by examination of telomere length and methylation status of 
the p16INK4a/Rb and/or p53/p21cip1 promoters in a cohort of 104 samples including cancerous 
and paired adjacent normal breast tissues from 52 patients. The result showed significantly 
shortened telomere length in the cancerous tissues especially in the grade two and three of breast 
cancer. After correlation study between the ratio of relative telomere length in the cancerous tissues 
and the traditional pathological parameters and clinical predictive markers, we could detect 
significant shortened telomere length in the samples with distant metastasis. Telomere shortening in 
cancer tissues was correlated with hypermethylation of the TP53, P21 and P16 promoter regions. 
The involvement of these cell cycle regulator pathways may allow for continuous cell division and 
critical telomere shortening. Shortened telomere length and hypermethylation of p53, p21cip1 and 
p16INK4a promoters may thus serve as biomarkers in breast cancer. 
 
 
First author s’ contribution:  
Ramin Radpour was involved in study design, performing the experiment, data analysis and writing 
the manuscript.  
Zeinab Barekati was involved in performing the experiment and writing the manuscript. 
 
 
 
 
109 Radpour et al. Research Article 
 
110 Radpour et al. Research Article 
 
111 Radpour et al. Research Article 
 
112 Radpour et al. Research Article 
 
113 Radpour et al. Research Article 
 
114 Radpour et al. Research Article 
 
115 Radpour et al. Research Article 
 
116 Radpour et al. Research Article 
 
117 Radpour et al. Research Article 
 
118 Radpour et al. Research Article 
 
119 Radpour et al. Research Article 
 
 
9. Submitted research manuscript: 
 
Integrated epigenetics of human breast cancer subtypes: synoptic 
investigation of targeted genes, microRNAs and proteins upon 
demethylation treatment 
 
Summary:  
Contribution of aberrant DNA methylation in tumorogenesis and silencing of tumor suppressor 
genes (TSGs) and microRNAs has been thoroughly investigated. Since these epigenetic alterations 
are reversible, it became of some interest to establish the complete early and late effects of the  
5-aza-2’-deoxycytidine (DAC) therapy in breast cancer using a pan-omics approach. In the 
presented work we have investigated multi-dimensional models to synoptically predict “early and 
late” systemic stable or transient effects of DAC at the level of the epigenome, the transcriptome, 
and the proteome for several breast cancer subtypes. In present study, the results give new 
therapeutic clues based on chemical modification of the pathological methylation patterns in breast 
cancer as well as investigation of some new molecular DAC targets and involved pathways. The 
presented approach might become a useful epigenetic treatment model for other human solid tumors 
in management of cancer patients. 
  
 
First author’s contribution: 
Ramin Radpour was involved in study design, making collaborations, performing part of the study, 
data analysis together with interpretation of biological interactions and writing the manuscript. 
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Abstract 
The contribution of aberrant DNA methylation in silencing of tumor suppressor genes (TSGs) 
and microRNAs has been investigated. Since these epigenetic alterations are reversible, it became 
of interest to determine the early and late effects of the 5-aza-2’-deoxycytidine (DAC) 
demethylation therapy in breast cancer within different molecular levels.  
Here we investigate a synoptic model to predict complete DAC treatment effects at the level of 
epigenome, transcriptome, and proteome for several human breast cancer subtypes. The present 
study assessed an effective treatment dosage based on the cell viability, cytotoxicity, apoptosis and 
methylation quantification assays for different breast cancer cell lines. Using the optimal treatment 
dosage, a highly aggressive and a non-aggressive lines were investigated at various time points 
using omics approaches such as MALDI-TOF MS, mRNA- and microRNA expression arrays, 2-D 
gel electrophoresis and LC-MS-MS.   
Complete molecular profiles of the studied subtypes including the biological interactions and 
possible early and late systematic stable or transient effects of the methylation inhibition were 
determined in depth. Beside the activation of several epigenetically suppressed TSGs, we also 
showed significant dysregulation of some important oncogenes, oncomirs, oncosuppressors 
miRNAs as well as drug tolerance genes/miRNAs/proteins in breast cancer related pathways.  
In present study, the results give new therapeutic clues based on chemical modification of the 
pathological methylation patterns in breast cancer as well as investigation of some new molecular 
DAC targets and involved pathways. The presented approach might become a useful epigenetic 
treatment model for other human solid tumors in management of cancer patients. 
 
Key words: Cancer genomics; Breast cancer; DNA methylation; microRNA; transcriptomics; 
proteomics; mass spectrometry. 
 
Introduction 
Aberrant DNA methylation patterns are associated with various human diseases [1] including 
cancer development [2]. Hypermethylation of human tumor suppressor genes (TSGs) leads to 
transcriptional inactivation followed by the gene silencing and  carcinogenesis [3].   
It was also discovered that microRNAs (miRNAs), endogenous non-coding RNAs with 19-25 
nucleotides in size, play important roles in various cellular processes including cellular growth, 
differentiation and apoptosis [4] that contribute to cancer development and progression [5]. 
Moreover, emerging studies reported that miRNAs are involved in promoter DNA methylation 
changes [6]. Also, DNA sequences encoding miRNAs were found to be a target of aberrant DNA 
methylation as well as protein-coding genes [7]. 
Genetic changes such as mutation or deletion are resulting in permanent loss of gene expression 
while epigenetic changes are often reversible and could be a useful target for developing new 
therapeutic strategies [8,9]. Reversal hypermethylation of silenced TSGs or miRNAs is increasingly 
being targeted for cancer therapy and prevention [10,11].  Moreover, these approaches are 
particularly appealing because DNA methylation inhibitors are considerably less toxic in non-
cancerous tissues compared to other anti-cancer drugs [12]. 
The 5-aza-2′-deoxycytidine (decitabine; DAC; Dacogen, Eisai, Inc.), has recently been 
approved by the Food and Drug Administration (FDA) for the treatment of patients with 
Myelodysplastic Syndromes (MDS) and leukemia [13,14]. Since DAC is one of the nucleotide 
analogs that is activated via phosphorylation by cellular deoxcytidine kinase and incorporated into 
the DNA, the result of this process is thought to lead to the depletion of methyltransferase activity 
and to demethylation of DNA [15].  Several strategies have been applied to optimize or enhance the 
activity of DAC in different human cancers including hematologic malignancies and solid tumors as 
a promising agent for cancer therapy [16].  
Pan-omics approaches at multiple molecular levels after DAC treatment for solid tumors are 
promising in opening new mechanistic insights in this area of cancer biology. These approaches 
enable to synoptically probe the epigenome, transcriptome and the proteome to understand 
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complete phenotype of treated cells such as any possible stable or transient changes as well as 
finding new therapeutic targets or pathways. Therefore we used DAC in this study as a tool 
compound to study focuses on multi-dimensional models to predict early and late effects of DAC 
on different subtypes of breast cancer using pan-omics approaches. 
 
Results and Discussion 
5-aza-2′-deoxycytidine (DAC) optimal dose-range finding 
In the present study, we have first identified the optimal, effective dosage of DAC by investigating 
the impact of concentrations in a range of 101 to 104 nM on seven different breast cell lines (six 
breast cancers and one control cell line) on the cell viability, cytotoxicity, apoptosis and DNA 
methylation.  
 
Quantification of cell viability, cytotoxicity and apoptosis  
The MultiTox-Glo Multiplex Cytotoxicity assay measured the relative number of live and dead 
cells in cell populations after treatment with increasing doses of DAC and could thus determine cell 
viability and cytotoxicity (Fig. 1a, b). Increasing the concentration of the DAC treatment (ranging 
from 101 to 104 nM) elevates the cytotoxicity and reduced the ratio of the cell viability in all cell 
lines. The results of these two measurements, cell viability and cytotoxicity, are inversely correlated 
as expected. The two concentrations, 101 and 102 nM DAC, showed viability higher than at EC50 for 
all studied cell lines and they revealed lower cytotoxicity compared to the other concentrations. 
 Two cellular caspases (caspase-3 and caspase-7) play a crucial role in apoptosis and are 
activated in a sequential cascade of cleavages from their inactive forms. To investigate the extent of 
cells apoptosis after exposure to different concentration of DAC, the enzymatic activity of caspase-
3/7 was measured (Fig. 1c). These cell death markers showed a dose dependent behavior; by 
increasing the DAC concentration the caspase-3/7 activities in all seven studied cell lines were 
elevated (Fig. 1c). The mean protease activities in the cells treated with 103 and 104 nM of drug 
were significantly higher than the lower dosages (P=0.001) while the mean activities of the caspase-
3/7 were similar for the both 101 and 102 nM concentrations of DAC.  
 
Quantitative methylation profiling of six breast cancer candidate genes  
Based on our previous study  where we assessed the methylation status of more than 42,528 
CpG sites in 22 different genes in cancerous breast tissues versus matched normal tissues [17], we 
selected six hypermethylated TSGs (BMP6, BRCA1, CST6, CDKN2A, CDKN1A and TIMP3) to 
assess the effective DAC dose range. We analyzed the methylation proportion of the six breast 
cancer candidate TSGs in all seven cell lines before and after treatment at increasing doses. For all 
studied genes one amplicon containing CpG rich islands (number of CpG sites higher than 20) was 
analyzed (Table 1). In total, we assessed six amplicons, containing 171 CpG sites per sample (total 
of 2,394 sites in all analyzed samples) (Table 1; Fig. 1d). The mean methylation quantity of the 
informative CpG sites per each gene was used to assess the methylation proportion of the candidate 
genes (Fig. 1d). DNA methylation proportion of the six studied genes were significantly decreased 
for all applied concentrations in the studied cell lines (P<0.01) (Fig. 1d). There were no significant 
differences on the extent of demethylation induced by DAC at concentrations of 102, 103 and 104 
nM, whereas hypomethylation of DNA achieved with these three mentioned concentrations was 
significantly more than the lowest treatment dosage (101 nM) (Fig. 1e). This data suggests that 102, 
103 and 104 nM dosages of DAC have more effective demethylation activity by significantly 
reducing the methylation proportion in the treated cells.  
Based on the results obtained from studies of the cell viability, cytotoxicity, apoptosis and the 
DNA methylation profile, the concentration 102 nM of DAC was identified to be the most favorable 
because of the less cytotoxicity and good efficiency in demethylation of DNA. This dose of DAC 
has been chosen for the further study on the early and late effects of the treatment using pan-omics 
assays for the MDA-MB231 and SKBR3 cell lines which are considered as a highly aggressive and 
a non-aggressive subtypes of breast cancer, respectively [18], together with the HB2 as a control 
breast cell line. 
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MRNA expression profiling 
Gene expression analysis was assessed expression microarray before treatment, directly after 
treatment and at five follow-up passages at “drug holiday” condition. Up- and down-regulated 
genes in at least in one of the analyzed passages of each cell line were considered as “union genes”. 
The common up- and down-regulated genes in different cell lines were considered as “intersection 
genes”. Annotated lists were created for the 991 union genes for the HB2, 431 union genes for the 
MDA-MB231 and 2406 union genes for the SKBR3 cell line (P<0.05, >2 fold change; Fig. 2-a1; 
Supplementary data 5). To interpret the significance of the study, first of all we focused on 
intersection genes within the two breast cancer cell lines and also on the intersection genes within 
all three studied cell lines. Besides that, expression profiles of tumor suppressor genes and 
oncogenes within were investigated in each cell line. 
The expression profile of 21 candidate genes using qRT-PCR technically confirmed the results 
of the expression array results and also demonstrated the reliability and reproducibility of the assay 
using the appropriate gene identifiers [19] with the high stringency criteria to filter out the assay 
noise [20].  
Intersection genes within cancer cell lines. In total 105 intersection genes were differentially 
expressed in the MDA-MB231and SKBR3 cell lines (Fig. 2-a5). The gene set analysis and GO 
enrichment scores revealed involvement of these genes in multicellular organismal process and 
processes that pertinent to the generation and maintenance of rhythms in the physiology of the cells 
(rhythmic process) (Fig. 2-a6). Pathway analyses showed that 36 out of 105 intersection genes are 
linked to breast neoplasms or metastasis and most of the significantly altered gene expressions in this 
category can potentially trigger cell proliferations (Fig. 2-a7).  As an example, CXCL3 (a small 
cytokine belonging to the CXC chemokine family that is also known as GRO3 oncogene) was up-
regulated after treatment in both cell lines, while JUP (a proliferation and oncogenesis marker) was 
up-regulated in the MDA-MB231 and down-regulated in the SKBR3 line (Table 2). 
Intersection genes within all three cell lines. There were 78 intersection genes which are 
differentially expressed in the two breast cancer cell lines (MDA-MB231and SKBR3) as well as in 
the control cell line (HB2) (Fig. 2-a2; supplementary data 2). Based on the gene set analysis and 
GO enrichment scores, these genes are mostly involved in developmental, immune system process 
and response to stimulus (Fig. 2-a3). Pathway analysis showed that 30 out of 78 intersection genes 
have roles in breast neoplasms, metastasis and / or cell proliferation (Fig. 2-a4) and below we 
mention some of these genes.  
For example, CDKN1A (P21) which plays a regulatory role in DNA replication and DNA 
damage repair and has strong tumor suppressor activity, was significantly up-regulated after 
treatment in all three cell lines. GJA1 (CX43) is a TSG which is associated with suppression of 
metastasis [21]. This gene was up-regulated in the HB2 while down-regulated in the MDA-MB231 
and SKBR3. One explanation for GJA1 down-regulation might be strong activation of IL8 in 
cancerous cell lines that has been also reported previously as a suppressor of GJA1 [22]. VEGFR 
was over-expressed in the SKBR3 and HB2. This gene was down-regulated in the MDA-MB231. 
Since the VEGFR gene is augmenting cell proliferation and oncogenesis, it can play an oncogenic 
role in carcinogenesis [23]. IL6 was very strongly expressed in all passages of the three studied cell 
lines as an early and late effect of DAC treatment. IL6 is a multifunctional regulator of immune and 
inflammatory responses, and an increase of its expression has been detected in multiple epithelial 
tumors including breast cancer [24]. IL6 is involved in the regulation of cell proliferation, survival, 
and metabolism. Additionally, high expression levels of IL6 are correlated with a poor clinical 
prognosis which can reflect its oncogenic role [25]. However, the involvement of IL6 in cancer is 
still quite controversial, as dichotomous roles for IL6 in both tumor-promoting and -suppressive 
activities have been reported [26]. Our data raise the question of whether combination of IL6-
targeted therapies (IL6 or IL6 receptor antagonists) with epigenetic therapy would be effective in 
treating breast cancer patients.  
Differentially expressed TSGs after DAC treatment. It is known that TSGs are 
hypermethylated in different tumor types as an early phenomenon during carcinogenesis [1,27]. In 
the present study, expression status of well-known TSGs was analyzed after treatment and follow-
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up passages (supplementary data 2). Up-regulation of epigenetically silenced TSGs is considered as 
a positive effect of DAC treatment. Several TSGs (e.g. CDKN1A, PTEN, CST6 BRCA1 and 
RASSF1) were differentially expressed after treatment (Table 2).  
The CDKN1A (P21) gene showed significant hypomethylation and activation in all three 
studied cell lines. CDKN1A was previously reported as a hypermethylated TSG in breast cancerous 
tissue [17]. PTEN is an essential component of the TP53 gene response upon DNA damage and it 
regulates p53 function through keeping Akt inactive and making Mdm2 incapable of translocation 
into the cell nucleus for degradation of p53 [28,29]. Recently, we showed that hypermethylation of 
the PTEN gene in breast cancer patients lacking TP53 mutations [30]. The epigenetic silencing of 
lysosomal cysteine protease inhibitor cystatin 6 (CST6) is more frequently observed in metastatic 
lesions than in primary cancers [31]. Our previous study revealed CST6 to be significantly 
hypermethylated in breast tumors as compared to the matched normal tissue [17]. CST6 was 
significantly reactivated after treatment in MDA-MB231. The two important TSGs, BRCA1 and 
RASSF1, which were hypermethylated in breast tumors [17] were significantly up-regulated in the 
SKBR3 after DAC treatment.  
Differentially expressed oncogenes after DAC treatment. It has been reported that some 
oncogenes are epigenetically hypomethylated and activated in human cancers [1]. The expression 
status of well-known oncogenes was analyzed after treatment and follow-up passages 
(supplementary data 2). Over-expression of oncogenes might be a negative feature of treatment with 
DAC, while down-regulation of oncogenes could consider as positive feature of treatment. 
Oncogenes such as RAB family genes, ETSA, CXCL1, CXCL2, CXCL3, ERBB2, MAFF, MERTK, 
MYC and PDGFB were differentially expressed after treatment (Table 2). For example, CXCL1 and 
-2 are two inflammatory cytokines that have a role in cell growth, proliferation, angiogenesis and 
diminishing the apoptosis; additionally they have an oncogenic role in carcinogenesis. Furthermore, 
depletion of CXCL1 and -2 expressions can inhibit metastasis [32].  
 
MicroRNA expression profiling 
To seek specific miRNA profile after treatment with DAC, the expression analysis was 
assessed before treatment, directly after treatment and at five follow-up passages at “drug holiday” 
condition. Annotated lists were created of the 74, 83 and 59 miRNAs which were differentially 
disregulated (P<0.05, >2 fold change) in all of the HB2, MDA-MB231 and SKBR3 cell lines 
respectively (Fig. 2-b1; Supplementary data 3 & 5). For each cell line, expression profile of 
intersection and union miRNAs within the passages, and their biological relevance are presented in 
supplementary data 3. To interpret the miRNA signatures, we focused on the intersection miRNAs 
within two breast cancer cell lines and the intersection miRNAs within all three studied cell lines.  
 
Intersection miRNAs within cancer cell lines. We detected eight intersection miRNAs (miR-
21, -24-2, -494, -193b, -181, let-7f, let-7g and let-7i) which were differentially expressed in the two 
cancer cell lines (Fig. 2-b4; Table 2). All eight miRNAs have a role in breast neoplasms, metastasis 
and cell proliferation (Fig. 2-b5).  
Intersection miRNAs within all three cell lines. In total 23 intersection miRNAs were 
differentially expressed in all three studied cell lines (Fig. 2-b2). Pathway analysis showed that 10 
out of 23 miRNAs (miR-106b, -126, -130a, -155, 15a, -210, -27a, -27b, -342 and -378) have role in 
breast neoplasms, metastasis and or cell proliferation (Fig. 2-b3). 
Differentially expressed oncosuppressor and oncomirs after DAC treatment. Numerous 
reports demonstrated that miRNAs contribute to the development and progression of cancer by 
acting as oncogenes or tumor suppressor genes [4,33]. Several oncosuppressor miRNAs showed 
significant up- and down-regulation after DAC treatment (Table 2). As an example of up-regulated 
oncosuppressor miRNAs; miR-155 was over-expressed during the scheduled follow up of the 
treatment in the both cancer cell lines while down-regulation of this  miRNA has been reported in 
breast cancer and the TSG  role was suggested for miR-155 due to decreasing cell proliferation and 
triggering the apoptosis [34].  
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As down-regulated oncosuppressor miRNAs after DAC treatment, we can mention the lower-
expression of two members of let-7 family, let-7f and let-7g, in both cancerous cell lines after DAC 
treatment. The expression of several members of the let-7 family including let-7f and let-7g, was 
previously reported to be down-regulated in breast cancer samples with either lymph node 
metastasis or distance metastases [34]. In addition, MiR-27b also showed down-regulation after 
treatment in all three analyzed cell lines. MiR-27b is considered as a regulator of CYPB1 and acts as 
tumor suppressor that is suppressed in breast cancer [35].   
As oncomirs, different miRNAs were differentially expressed after treatment (Table 2). From 
this group miR-21 has been reported as a potential oncogene which promotes cell survival and 
proliferation [36]. In breast cancer, miR-21 is overexpressed [34] and by targeting multiple tumor 
suppressor genes, such as PTEN, PDCD4, TPM1, and MASPIN has been implicated in the 
acquisition of invasiveness and in promoting tumor metastatic properties in breast cancer [37]. 
Moreover, miR-21 overexpression has been associated with an advanced clinical stage and lymph 
node metastasis in human breast cancer [38]. Interestingly, miR-21 was significantly down-
regulated in both MDA-MB231 and SKBR3 (P<0.001) after treatment that indicates the anti-cancer 
effect of the treatment. As another important example, miR-27a plays an important role in breast 
cancer by suppressing the expression of the transcription factors ZBTB10/RINZF, and subsequently 
increasing several angiogenic molecules, such as Survivin, VEGF and VEGFR1 [39]. A previous 
report indicated over-expression of the miR-27a in breast cancer [40]. Our results demonstrated that 
DAC treatment can significantly suppress miR-27a expression. 
 
Protein expression profiling 
Proteins from the three selected cell lines were analyzed by 2D gel electrophoresis. We could 
detect a total of 27 intersection significantly up- and down-regulated proteins (4 in HB2, 8 in MDA-
MB231 and 15 in SKBR3 cell lines) (Fig. 3A; Supplementary data 4). Principal component analysis 
(PCA) showed similarity between different treatment passages and in a dendrograms, differentially 
expressed proteins clustered in different groups based on their expressional profile (Fig. 3A). In the 
control breast cell line (HB2), the number of differentially expressed proteins was lower than in the 
other two cancerous cell lines. The dendrogram of HB2 revealed two clusters and the two clusters 
revealed approximately the same expression level of the untreated cells. In the MDA-MB231 (a 
highly aggressive cancerous line), proteins whose expression changed significantly, were 
categorized into two clusters. One cluster showed fluctuating up-regulation along the passages 
while the other returned to the level of untreated cells. Protein expression profiles in the SKBR3 
(non- aggressive cancerous line) were divided into three clusters. Interestingly, all three clusters 
ended with over-expression and are attributable to late effect of treatment. The protein expression 
profiles in two cancerous cell lines are related to long term effects of the treatment and could help to 
better define treatment intervals. The fold change, P value, theoretical pI and spot volumes are 
summarized in supplementary data 4. 
In total, 18 candidate spots were excised and submitted to LC-MS-MS analyses for protein 
identification. The identified proteins, gene ID, theoretical molecular weights (kDa), number of 
identified peptides and the percentage of amino acid coverage are shown in Table 3. In some 
excised spots we identified a single protein, in some others multiple isoforms, and yet in others we 
observed several proteins in a single spot. In all instances where the probability of correct 
determination was close to 100% (as determined by Scaffold) we have checked the observed 
molecular mass and pI value (according to spot position on the gel) with the MS identification. We 
thoroughly checked peptides that might have been due to neighboring contamination (needle 
transfer). In situations where peptide detection leads to an unambiguous protein identification and 
spurious a peptide was detected, the presence of the spurious peptide(s) was disregarded. This is 
highly speculative and doesn’t bring you any further: either you identify something properly or not! 
I’d leave that away. 
Notably, in the spot 1543 (SKBR3 cell line) we could identify four different isoforms of the 14-
3-3 protein which were confirmed with two different replicates referring to the same spot; their 
calculated molecular masses or pI values deviated from the observed ones (and also from the main 
126 Radpour et al. Research Article 
 
set of polypeptides). This highly conserved protein family is a large family of 25–30kDa acidic 
proteins and has seven homologous isoforms in mammalian cells which are involved in a variety of 
biological interactions, cell-cycle progression, apoptosis, and mitogenic signaling, such as the 
ATM-p53 pathway, suggesting that they may play a role in tumorigenesis [41]. 14-3-3 theta is an 
adapter protein implicated in the regulation of both general and specialized signaling pathways by 
binding to a large number of partners, usually by recognition of a phosphoserine or 
phosphothreonine motif.  
Interestingly, five differentially expressed genes detected by transcriptomic analysis were also 
identified by mass spectrometry at the proteome level, which indicated similar expression trends at 
both, the transcriptome and proteome (Supplementary Data 4). The results implicated that two of 
these five proteins (Sod2 and Pebp1) were detected in one spot (SKBR3; 1486). These data support 
the mass spectrometry results for those cases where more than one protein species were detected 
within one spot (Table 3).   
Following the protein identification, the molecular function, biological processes, and 
subcellular localization was categorized using the PANTHER gene ontology database 
(http://pantherdb.org) and ResNet® 7 (Mammal) database. The analyzed data showed that 28 out of 
41 detected proteins/ isoforms in the three analyzed cell lines are linked to neoplasms, metastasis or 
carcinogenesis (supplementary data 4). 
 
Integrative, pan-omics 
Possible crosstalk between all identified union genes, miRNAs and proteins with a reported 
role to carcinogenesis, was investigated in this study. In total 11 genes, 11 miRNAs and 10 proteins 
showed interesting regulatory interactions (Fig. 3B). 
  
 Dysregulation of metastasis related genes/miRNAs. In order to screen the direct effect of the 
DAC treatment on tumor metastasis, we analyzed the expression profile of PDCD4, DHFR, and 
HOXD10, three of the most promising genes implicated in the metastatic process [40,42]. Among 
these metastasis related TSGs, only PDCD4 was altered by the scheduled treatment and was 
significantly up-regulated in the highly aggressive cell line (MDA-MB231) and significantly down-
regulated in the non-aggressive cell line (SKBR3) (Fig. 4A). The two miRNAs (miR-21 and miR-
183), have complementary sites for the 3’-UTR of PDCD4 and are considered to be possible 
suppressors of this gene [42,43]. Interestingly, the expression analysis revealed down-regulation of 
miR-21 in the MDA-MB231, which was inversely correlated to PDCD4 in the same cell line 
(P<0.001) (Fig. 4-a1). This finding is in line with previous reports suggesting miR-21 as a potential 
down-regulator element for the PDCD4 gene [42,43]. However, miR-183 did not show any 
significant correlation with the expression of PDCD4 in either of the two breast cancer cell lines 
(Fig. 4A), which is in contradiction with previous reports [44]. This suggests that miR-21 (rather 
than the miR-183) is responsible for regulation of PDCD4. 
Furthermore, CXCR4 as one of 19 known human G protein–coupled chemokine receptors is 
specifically implicated in cancer metastasis and HIV-1 infection [45]. CXCR4 has been associated 
with more than 23 cancer types promoting metastasis, angiogenesis, tumor growth and poor 
prognosis of patients. Over-expression of CXCR4 has also been shown in ~10% of the tumors [46]. 
There is the possibility of using CXCR4 as a therapeutic target against solid tumors [47]. 
Interestingly, CXCR4 was significantly down-regulated in all scheduled follow-ups after 
demethylation treatment in the MDA-MB231 cell line (Fig. 4-a1). This finding suggests that down-
regulation of CXCR4 can be a secondary response to the demethylation of other upstream regulatory 
elements in the aggressive form of breast cancer. 
Taken together, over-expression of PDCD4, inhibitor of cell proliferation and invasion through 
increasing the apoptosis, and conversely down-regulation of CXCR4, activator of cell proliferation 
and invasion, after treatment with DAC suggest reduction of the invasion and metastasis for the 
highly aggressive subtype of breast cancer.  
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Suppression of the ERBB2/HER2 receptor in the non-aggressive breast cancer subtype 
after DAC treatment. The estrogen receptor (ER), progesterone receptor (PR) and ERBB2/HER2 
markers are used as prognosis indicators  in breast cancer to stratify patients for appropriately 
targeted therapies [48]. After DAC treatment there were no significant changes in hormonal receptor 
expression status (ESR1, ESR2, PGR and ERBB2) for the HB2 (breast epithelial cell line) and 
MDA-MB231 (triple hormonal negative cell line). In the SKBR3 (ERBB2/HER2 positive cell line), 
ERBB2 showed a steady down-regulation after treatment (Fig. 4B). The ERBB2 is a proto-oncogene 
that encodes a member of the epidermal growth factor (EGF) receptor family of tyrosine kinases. 
Amplification and/or over-expression of this gene have been reported in numerous cancers, 
including breast and ovarian tumors [49]. To understand the molecular mechanism of ERBB2 down-
regulation after demethylation treatment with DAC, we analyzed the expression profile of negative 
upstream regulators (Fig. 4-b1). From 21 candidates, two genes (BRCA1 and MYC) and one miRNA 
(miR-125b) showed significant up-regulation after the treatment. From these three negative 
regulators, expression of two (MYC and miR-125b) were inversely correlated with ERBB2 
expression (P<0.001) (Fig. 4-b2). MiR-125b, which was previously reported to be down-regulated 
in breast cancer [34], is involved in the regulation of ERBB2 and ERBB3, two important tyrosine 
kinase receptors, impairing the downstream signaling pathway and the ability of the cells to grow 
and invade [50]. MiR-125b was significantly over-expressed as early and late effects only in the 
SKBR3 cells (Table 2). Interestingly, in this regard we could identify a positive upstream regulator 
protein (Pdia6 protein) by mass spectrometry, which presented a significant correlation with ERBB2 
down-regulation (P<0.05) (Fig. 4-b3). Pdia6 has activator role for ERBB2 can contribute to cell 
proliferation and breast neoplasm [51]. 
Deregulation of drug resistance related genes/miRNAs. The relatively rapid acquisition of 
resistance to cancer drugs remains a key obstacle for a successful cancer therapy [52]. Cancer-
initiating cells have been proposed as potential culprits because of their capacity to escape from the 
drug effects by becoming quiescent [53]. To get insights into the underlying mechanisms of drug 
resistance against DAC, we checked the expression status of more than 40 candidate genes 
suggested by the pathway analysis that are involved in a variety of resistance mechanisms. From 
these candidate genes/proteins, 12 genes detected by differential transcriptomics (IL6, TGFB1, 
VEGFA, SERPINB5, FGF2, SFN, ERBB2, RAD51, CSF2, COL18A1, MDK and TNFSF10) and four 
proteins detected proteomically (P4hb, Sod2, Arhgdia and Glo1) were mostly up-regulated after 
DAC treatment (Table 2; Fig. 5). At the protein expression level, significant alterations over the 
scheduled follow up were found for the P4hb protein in the HB2 cells, Sod2 and Arhgdia proteins 
in the MDA-MB231 cells, and for the Glo1 protein in SKBR3 cells (Fig. 5).  
The miRNAs expression alteration in response to chemotherapy was previously studied and 
showed that Let-7i, miR-181a, -221, -27b, -34a, -424, -638 and -768 were up-regulated and miR-17, 
-21 and -28 were down-regulated after exposure to several drugs [54]. Our analysis of the genome-
wide effects of DAC on cellular miRNAs implicated significant down-regulation of miR-28 in all 
three cell lines, miR-21 in both cancerous cell lines and miR-17 in the non-aggressive cell line 
(Table 2; supplementary data 5). At least three miRNA families were up-regulated: MiR-638 in all 
three cell lines, miR-34a in the highly aggressive line, miR-424 in non-aggressive line, in a 
concordance with previous reports [54]. Other miRNAs were down-regulated upon treatment with 
DAC in all cell lines (miR-181a and -27b). In some instances Let-7i and miR-221 presented 
different responses than reported [54]. In conclusion, most of the miRNAs with a role in drug 
resistance were down-regulated after treatment with DAC (Table 2) which may suggest less 
resistance controlling behaviors of miRNAs after treatment with this drug. 
Prominent regulatory role of miR-24 on the methylated P16-INK4A gene in the non-
aggressive breast cancer subtype. P16-INK4A acts as an inhibitor of CDK4 kinase and in 
cooperation with TP53 has regulatory role for cell cycle G1 control. This gene is an important 
tumor suppressor gene which is frequently silenced (through hypermethylation of specific CpG 
islands in the promoter, mutation, homozygote deletion or other epigenetic regulators) in many 
nonendocrine tumors [55], and these alterations may be predictive of recurrence, tumor growth, or 
aggressiveness [27]. Our previous study showed significant promoter hypermethylation of 
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CDKN2A (P16-INK4A) gene in the breast cancer tissues as well as in the circulating cell free DNA 
(cff DNA) of patients [17,56]. In the present study, P16-INK4A was not transcriptionally active and 
after treatment with DAC showed no significant change in the expression level in the both cancer 
cell lines (Fig. 6-a1 & 2). It is reported that P16-INK4A has homozygote deletion (c.1_471 del 471) 
in the MDA-MB231 cell line [57]. Our data from full gene sequencing also confirmed homozygote 
deletion in this cell line (data not shown).  
The SKBR3 cell line showed significant reduction in the methylation proportion of the P16-
INK4A promoter (P<0.05) directly after treatment with DAC (Fig. 6-a3). In spite of CDKN2A 
hypomethylation induced by DAC, there wasn’t any change in the expression level of the gene (Fig. 
6-a2). In order to screen the possible mutation in the P16-INK4A, we performed full gene 
sequencing on the promoter region, 5’UTR, three exons including exon/intron boundaries (exon 1-
3) and 3’UTR. The sequencing result showed two different mutations/polymorphisms, a 
heterozygote transition mutation in the 5’UTR (c. 81 G>A) and a homozygote transversion 
mutation in the 3’UTR (c.771 G>C) of the gene (Fig. 6-a4). These two mutations/polymorphisms 
are located in the UTR part of the gene that may not be the cause of lacking P16-INK4A expression 
in the SKBR3. 
Further investigation demonstrated steady up-regulation of miR-24 in the SKBR3 cell line after 
treatment and at all follow-up passages (Fig. 6-a6). MiR-24 has intriguing complementarities to the 
3’-UTRs and controlling region (CR) of  the P16-INK4A and suppresses the gene (Fig. 6-a5) [58]. 
The two found mutations/polymorphisms are not located in the complementary site of the miR-24 
therefore they cannot change the binding affinity of the miR-24 to the gene (Fig. 6-a7). The 
expression of miR-24 showed significant inverse correlation to P16-INK4A which might provide an 
explanation for P16-INK4A shut down in the non-aggressive cell line. These findings highlight the 
specific role of the epigenetic regulation of TSGs during carcinogenesis. 
Inverse correlation of up-regulated miR-29b as methylation suppressor with expression of 
DNMT3A in the non-aggressive cell line. The miRNA (miR)-29 family (29a, 29b, and 29c) has 
intriguing complementarities to the 3’-UTRs of DNA methyltransferase (DNMT)3A and -3B (de 
novo methyltransferases), two key enzymes involved in DNA methylation, that are frequently up-
regulated in solid tumors and associated with poor prognosis. In lung squamous cell carcinomas, 
elevated Dnmt1 expression has been reported as a poor prognosis factor. Moreover, elevated 
expressions of both Dnmt1 and Dnmt3B have been shown to be correlated with hypermethylation 
of TSG promoters [59]. It was shown that expression of miR-29s, especially miR-29b, is directly 
targeting both DNMT3A and -3B and is inversely correlated to their expression in lung cancer 
tissues [60,61]. In the present study, after demethylation treatment, the expression of miR-29b was 
inversely correlated with DNMT3A expression in the non-aggressive form of breast cancer 
(SKBR3) and down-regulated expression levels of DNMT3A (Fig. 6B). Additionally, in the SKBR3 
cell line with up-regulation of miR-29b and steady down-regulation of DNMT3A represented an 
almost 10 fold increase of number of the differentially expressed genes after demethylation 
treatment compared to the MDA-MB231 cell line (Fig. 6-b5 vs. Fig. 6-b3) was found. The present 
data highlights a more prominent role of Dnmt3A in the hypermethylation of promoters in the 
studied breast cancer subtypes than Dnmt1 and Dnmt3B. This finding also suggests that a 
combination of chemical demethylation treatment with DNMT inhibitors (decitabine or azacitidine) 
with enforced expression of miR-29b in breast cancer might have a synergistic hypomethylation 
effects that may turn to give a better disease response in breast cancer along with the more robust 
gene re-expression especially for the epigenetically silenced TSGs.  
To understand the molecular mechanism of miR-29b deregulation, we analyzed the expression 
profiles of two important upstream suppressors (miR-152 and miR-455) [18]. Both of the miR-29b 
suppressors, miR-152 and miR-455, were over-expressed in the MDA-MB231 cell line that might 
have caused miR-29b down-regulation in this cell line. In the SKBR3 cell line along with the over-
expression of miR-29b, miR-455 was also up-regulated whereas miR-152 did not show any 
significant changes. The present data suggest a prominent inhibitory effect of miR-152 rather than 
miR-455 on the regulation of miR-29b emphasizing on the various controlling behaviors of 
miRNAs in certain types of cancer.  
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Conclusions 
The aberrant DNA methylations of the genes/miRNAs which are involved in malignant 
phenotypes provide interesting targets for chemotherapeutic intervention. To the best of our 
knowledge, the study presented here is the first pan-omics approach to synoptically identify 
epigenetic, transcriptom and proteome-wide alterations after effective demethylation treatment with 
DAC in the context of breast cancer subtypes.  
The results of our synoptic pan-omics analysis (from a single sample aliquot to reduce 
heterogeneity between samples), provide a comprehensive view of DAC treatment defined by stable 
or transient early and late systematic effects in the model of cancer or non-cancer specific changes. 
We investigated DAC targets in depth (e.g. genes, miRNAs and proteins) and identified new 
involved pathways as well as biological interactions in between the molecular levels that may 
correlate with particular steps in breast neoplasm including cell proliferation, cell/tissue invasion, 
oncogenesis, angiogenesis, apoptosis, neoplasm metastasis and senescence.  
Additionally, in the presented study, beside the activation of several epigenetically suppressed 
TSGs, we also showed significant down-regulation of some miRNAs with oncogenic functions in 
breast cancer cell lines (e.g. miR-21) as well as over-expression of some miRNAs with tumor 
suppressor functions (e.g. miR-155) that highlights the potential of a miRNA-based therapy in 
breast cancer. The presented approach might become a useful model for other human solid tumor 
malignancies, alone or in combination with other treatments such as enforced targeted therapies for 
miR-29b and / or IL6 (IL6 or IL6 receptor antagonists). 
Achieving a successful therapy with DAC requires the application of repetitive optimal-dose 
cycles with regular intervals that may allow efficient incorporation of the drug into the newly 
synthesized DNA undergoing mitosis during each treatment. The obtained results provide a 
rationale for developing therapeutic strategies based on reactivation of epigenetically silenced 
genes/miRNAs in breast cancer.  
 
Materials and Methods 
 An optimal treatment dose screening for DAC was done based on viability, toxicity, apoptosis 
and methylation alterations for six breast cancer cell lines (MDA-MB-231[62], MCF-7[63], 
HS578T[64], BT549[65], T47D[66] and SKBR3[67]) and a breast epithelial cell line (HB2)[68] as 
control.  
Three selected cell lines (HB2, MDA-MB231 and SKBR3) were treated with an optimal dose 
of DAC (102 nM, ~ 5 days), then cells were cultured up to 10 passages at “drug holiday” condition. 
Simultaneous extraction of DNA, RNA, miRNA and proteins was performed according to a 
previously published protocols [69]. 3-dimentional follow-up including gene expression, 
microRNA expression and proteomics analysis was assessed before treatment, after treatment and at 
five point scheduled follow-up (1st, 3rd, 5th, 7th and 10th passages). Microarray expression profiling 
of mRNAs and miRNAs were conducted using the Human Genome 133 Plus 2.0 GeneChips and 
Affymetrix GeneChipR miRNA array v1.0 respectively using protocols recommended by the 
manufacturer (Affymetrix). All analysis was based on expression values generated by using the 
Robust Multi-array Analysis (RMA) condensing methods. The differentially expressed mRNAs and 
miRNAs were defined using Partek Genomics Suite software. All mRNA microarray data compiled 
for this study is made publicly available on GEO (http://www.ncbi.nlm.nih.gov/geo/) under 
accession number GSE28968 and miRNA microarray data under accession number GSE28969. To 
validate the microarray findings, quantitative real-time (qRT) PCR was performed for 28 candidate 
genes and 15 candidate miRNAs. The proteomic profile was investigated using two-dimensional gel 
electrophoresis (2DE) based on the previously published methods [69] and analyzed with 
Progenesis SameSpot software. The protein spots of interest were excised from the gels and 
analyzed by capillary liquid chromatography tandem MS (LC-MS-MS). Protein Identification was 
done using TurboSequest software [70]. Gene networks and canonical pathways including protein-
protein interactions as well as genes-miRNAs interactions were identified using the Pathway 
Studio® software and ResNet® (Mammal) database). The complete materials and method is 
presented in Supplementary Data 1. 
130 Radpour et al. Research Article 
 
Additional Information  
The complete materials and method is available in supplementary data 1. The complete gene 
expression profiles of three cell lines are presented in supplementary data 2. The complete 
microRNA expression profiles of three cell lines are summarized in supplementary data 3. The 
complete proteomic profiles of three cell lines are shown in supplementary data 4.  
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Table 1. High-throughput methylation analysis of CpG sites per amplicon for the 10 candidate genes. 
Genes Amplicon size (bp) 
Total No. of 
CpG sites in 
amplicon 
No. of analyzed 
CpG sites in 
amplicon 
No. of analyzed CpG 
sites per amplicons 
Single Composite 
BMP6 397 37 30 11 19 
BRCA1  413 30 15 10 5 
CST6 445 49 27 15 12 
CDKN2A 580 62 36 13 23 
CDKN1A 419 30 19 10 9 
TIMP3 441 51 44 11 33 
The in silico digestion was performed for the T-cleavage assay. The percentage of total CpG sites in the amplicon is divided into 
single sites (single CpG sites) and composite sites (two or more adjacent CpG sites fall within one fragment, or when fragment 
masses are overlapping).  
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Table 2. Differentially expressed well-known cancer related and drug tolerance related TSGs, oncogenes, miRNAs and 
proteins after DAC treatment in breast cancer subtypes. 
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Tumor suppressor 
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CDKN1A 
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CDKN1A 
FLCN 
RASSF1 
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FAT3 
PTEN 
GJA1 (CX43) CADM1 
CDKN1B 
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ING4 
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PDGFB 
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CXCL3 
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LCN2 
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BRAF 
CXCL2 
CXCL3 
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LCN2 
MYC 
 RAB1S MERTK ERBB2 
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Drug tolerance 
related genes 
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MDK 
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VEGFA 
CSF2 
FGF2 
IL6 
SERPINB5 
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 SERPINB5 COL18A1 
VEGFA 
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Tumor suppressor 
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miR-125a 
miR-125b 
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miR-15a 
miR-210 
miR-27b 
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let-7g 
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miR-15a 
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OncomiRs   miR-494 
miR-181a 
miR-378 
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miR-181a 
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 miR-27a 
miR-106b 
miR-130a 
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Drug tolerance 
related miRNAs 
 
 
miR-638 
miR-768 
miR-638 
miR-34a 
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miR-424 
miR-768 
 miR-28 
miR-181a 
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miR-21 
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miR-27b 
miR-768 
let-7i 
miR-28 
miR-21 
miR-17 
miR-181a 
miR-27b 
let-7i 
Pr
ot
ei
n 
 
ex
pr
es
sio
n 
**
* 
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Drug tolerance 
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The complete data include both early and late up- and down-regulations, P values and fold changes are presented in 
supplementary data. * Supplementary data 2 & 5; ** Supplementary data 3 & 5; *** Supplementary data 4. 
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Table 3. Detected proteins using capillary liquid chromatography tandem MS within three analyzed cell lines. 
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eukaryotic translation initiation factor 3 subunit I EIF3I 8668 gi|4503513 37 9 28 
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Galectin-7 LGALS7 3963 gi|3891470 28 3  
glutathione S-Transferase M2-3 GSTM2 2946 gi|5822511 26 5 21 Replica (b) 
1486 
manganese superoxide dismutase SOD2 6648 gi|34707 25 5 12 
 phosphatidylethanolamine-binding protein 1 PEBP1 5037 gi|4505621 21 5 30 
regulator of G-protein signaling 10 RGS10 6001 gi|18266777 20 4 12 
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1590 chromobox protein homolog 1 CBX1 10951 gi|5803076 21 2 10  
1633 glyoxalase-I GLO1 2739 gi|5020074 21 5 22  
2162 canopy homolog 2 isoform 1 precursor CNPY2 10330 gi|7657176 21 2 14  
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o 
1727 GTP-binding protein SAR1a SAR1A 56681 gi|9910542 22 3 17  
proteasome subunit beta type-2 PSMB2 5690 gi|4506195 23 3 19 
Fo
ur
 
960 
spliceosome RNA helicase BAT1 BAT1 7919 gi|4758112 49 13 32 
 
26S proteasome non-ATPase regulatory subunit 5 PSMD5 5711 gi|4826952 56 7 15 
beta-tubulin TUBB1 81027 gi|2119276 49 5 14 
protein disulfide-isomerase A6 PDIA6 10130 gi|5031973 48 5 15 
(aa: amino acids) 
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Fig. 1.  Dose response screening within six breast cancer cell lines (MCF7, MDA-MB231, T47D, SKBR3, HS578T 
and BT549) and epithelial breast cell line (HB2) as a control. a-b) Multiplex quantification of the cell viability and 
cytotoxicity protease activities upon demethylation treatment with DAC (digitonin treated cells were considered as cell 
death control). c) Quantification of caspase-3 and caspase-7 activities as a measure of apoptosis. d-e) Methylation 
profiling of six candidate tumor suppressor genes (red clusters indicate 0% methylated, yellow clusters indicate 100% 
methylated, color gradient between red and yellow indicates methylation ranging from 0-100, and black clusters 
indicate  not analyzed CpG sites).  
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Fig. 2.  A) Gene expression matrix of the HB2, MDA-MB231 and SKBR3 cell lines. a1) The number of significant 
up/down-regulated genes of three analyzed cell lines. a2) Expression profiles of 78 intersect genes among all three cell 
lines as non-cancer specific changes. a3) Gene set analysis and GO enrichment score of 78 genes (a value of three or 
higher corresponds to a significant over expression; P<0.05). a4) Pathway analysis of 30 out of 78 intersect genes that are 
linked to breast neoplasms, metastasis and/or cell proliferation.  a5) Expression profiles of 105 intersect genes between 
the MDA-MB231 and SKBR3 as cancer specific changes. a6) Gene set analysis and GO enrichment score of 105 genes. 
a7) Pathway analysis of 36 out of 105 intersect genes that are linked to breast neoplasms, metastasis and or cell 
proliferation.   
B)  MicroRNA expression matrix of the HB2, MDA-MB231 and SKBR3 cell lines. b1) The number of significant 
up/down-regulated miRs of three analyzed cell lines. b2) Expression profiles of 23 intersection miRs among all three 
analyzed cell lines as non-cancer specific changes. b3) Pathway analysis of 10 out of 23 intersection miRs that are linked 
to breast neoplasms, metastasis and/or cell proliferation.  b4) Expression profiles of 8 intersection miRs between the 
MDA-MB231 and SKBR3 as cancer specific changes. b5) Pathway analysis of 8 intersection miRs as cancer specific 
changes that are linked to breast neoplasms, metastasis and or cell proliferation.   
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Fig. 3.  A) Proteomics analysis of the three studied cell lines. (a1 – a3 left panel) Proteomic images of representative 
gels of the three cell lines HB2, MDA-MB231 and SKBR3 with indicated spot positions excised for mass spectrometry 
analysis; spot picking performed from up/down-regulated intersection proteins. (a1 – a3 middle panel) PCA analysis of 
intersection proteins from passages 1, 3, 5, 7 and 10 from the three cell lines. (a1 – a3 right panel) Clustering and 
classification of significantly up/down-regulated proteins based on their profiles throughout the passages. 
B) Crosstalk between 3-dimensional Omics. Predicted interactions between intersection genes, miRNAs and proteins. 
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Fig. 4.  A) Regulation of PDCD4 and CXCR4 genes as important indicators of metastasis and prognosis before and after 
treatment in two studied cancerous cell lines. a1-2) Expression profiles of PDCD4 and CXCR4 genes and regulatory 
microRNAs in the MDA-MB231 and SKBR3 cell lines, respectively. a3) Pathway analysis predicts the role of PDCD4 
and CXCR4 in cancerogenesis and shows the upstream regulatory miRs. B) Mechanism of ERBB2 receptor down-
regulation in the SKBR3 (non-aggressive breast cancer cell line). b1) Pathway analysis shows negative upstream 
regulators of ERBB2 gene and PDIA6 as an example of positive regulators.  b2) Expression profiles of ERBB2 and 
some negative regulators (BRCA1, MYC and miR-125b) that demonstrated significant changes during treatment. b3) 
Expression profile of Pdia6 protein as a positive regulator of ERBB2 that is detected by proteomics analysis.  
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Fig. 5.  Drug resistance after treatment with DAC. Candidate genes and proteins that are involved in drug resistance 
with significant expression changes after treatment (A). Cell lines: HB2 (B), MDA-MB231 (C) and SKBR3 (D). 
Expression profiles of 12 candidate genes (TGFB1, VEGFA, SERPINB5, FGF2, SFN, ERBB2, RAD51, CSF2, 
COL18A1, MDK, TNFSF10 and IL6) (b1, c1 and d1). Expression profiles of candidate proteins: P4hb (b2), Sod2 (c2), 
Arhgdia (c3) and Glo1 (d2). 
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Fig. 6. A) Epigenetic regulation of P16-INK4A tumor suppressor gene. a1) Expression profile of P16-INK4A in treated 
and untreated cell lines; in the cancerous cell lines MDA-MB231 and SKBR3 no expression was detected. a2) 
Expression profile of P16-INK4A within all analyzed passages according to normalized Ct values (∆Ct). a3) 
Methylation proportion of informative CpG sites of P16-INK4A in the SKBR3 cell line. a4) Full gene sequencing of 
P16-INK4A revealed a heterozygote transition mutation in 5’UTR and a homozygote transversion mutation in 3’UTR of 
the gene. a5) Pathway analysis predicts the role of has-miR-24 (MIRN24) as down-regulator of the P16-INK4A. a6) 
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Expression profile of has-miR-24 in the non-aggressive breast cancerous cell line (SKBR3) versus control breast cell 
line (HB2). a7) Comparison of miR-24 recognition site with the location of found mutations in the mature P16-INK4A 
mRNA. 
B)  Role of has-miR-29b (MIRN29b) as methylation suppressor during chemical methylation treatment. b1) Pathway 
analysis predicts the inhibitory effects of MIRN29b for DNMT3A and DNMT3B genes and shows negative upstream 
regulators of MIRN29b. b2) Expression profiles of MIRN29b, DNMT3A, DNMT3B and regulatory microRNAs in the 
MDA-MB231 cell line. b3) The number of significant up/down-regulated genes within different passages of the MDA-
MB231. b4) Expression profiles of MIRN29b, DNMT3A, DNMT3B and regulatory microRNAs in the SKBR3 cell line. 
b5) The number of significant up/down-regulated genes within different passages of the SKBR3. 
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Supplementary Data 1 
Complete Materials and Methods 
 
Eligibility criteria and study design 
An optimal DAC concentration for the effective treatment was screened on the cell viability, 
toxicity, apoptosis and DNA methylation for the seven breast cell lines (six breast cancers and a 
breast epithelial cell line as control). Pan-omics analysis at multiple molecular levels including 
epigenetic, transcriptomic (mRNA and microRNA expression) and proteomic analysis was 
performed before treatment, directly after treatment and at five follow-up passages at “drug 
holiday” condition for the two selected breast cancer cell lines and the control cell line of the step 
(a) for up to 10 passages. The study design workflow is illustrated in figure 1. 
 
 
Fig. 1.  The study design workflow. a) Screening for the optimal DAC treatment concentration on the cell 
viability, toxicity, apoptosis and DNA methylation for the six cancerous and a normal breast cell lines. b) 
Pan-omics follow-up (mRNA expression, microRNA expression and proteomics analysis) after treatment up 
to passage 10 for the two cancerous and a normal breast cell lines. 
 
Cell lines and culture conditions 
A total of six breast cancer cell lines (MDA-MB-231, MCF-7, HS578T, BT549, T47D and 
SKBR3) and a breast epithelial cell line (HB2) were subjected for this study. The characteristics and 
media conditions are summarized in the table 1.  
 
 
Table 1. Source, clinical and pathological features, and culture conditions of used cell lines. 
 
Cell 
line 
Gene 
cluster 
Receptor status TP53 Source Tumor Type Culture media 
Culture 
conditions ER PR ERBB2/HER2 
HB2 Lu + + - ++WT P.Br - DMEM, 10% FBS, I, H  37oC, 5% CO2 
BT549 BaB - - - ++M P.Br IDC, pap RPMI, 10% FBS 37
oC, 5% CO2 
HS578T BaB - - - +M P.Br IDC DMEM, 10% FBS 37oC, 5% CO2 
MCF7 Lu + + - +/-WT PE IDC DMEM, 10% FBS 37oC, 5% CO2 
MDA-
MB231 BaB - - - ++
M PE AC DMEM, 10% FBS 37oC, 5% CO2 
SKBR3 Lu - - + + PE AC McCoys 5A, 10% FBS 37oC, 5% CO2 
T47D Lu + + - ++M PE IDC RPMI, 10% FBS 37oC, 5% CO2 
AC, adenocarcinoma; BaB, Basal B; IDC, invasive ductal carcinoma; Lu, luminal; Pap, papillary; P.Br, primary breast; PE, 
pleural effusion.  
ER/PR/HER2/TP53 status: ER/PR positivity, HER2 overexpression, and TP53 protein levels and mutational status (obtained 
from the Sanger web site; M, mutant protein; WT, wild-type protein) are indicated.  
Media conditions: FBS, fetal bovine serum; I, Insulin (0.01 mg/ml); H, hydrocortisone (500 ng/ml);  
DMEM, Dulbecco’s modified Eagle’s medium, GIBCO #11965-092; RPMI, RPMI medium 1640, GIBCO #27016-021.  
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DAC treatments 
Cells were seeded (2 X l05 cells / T75 flasks) for 24h then media were removed and cells were 
freshly exposed to the DAC (Sigma Chemical Co., Switzerland) at concentrations of l01, l02, l03 or 
104 nM in suspension culture every 24h until cultured cells reached 80-85 % confluence (~5 days). 
The cells were split for 10 follow-up passages at “drug holiday” condition.  
 
Multiplex quantification of cell viability and cytotoxicity protease activities 
Multiplex quantification of the cell viability and cytotoxicity protease activities were assessed 
using the MultiTox-Glo Multiplex Cytotoxicity® Assay kit (Promega AG, Dübendorf, Switzerland) 
according to the manufacturer´s instructions. In this assay the two protease activities were measured 
(one as a marker of cell viability, and the other as a marker of cytotoxicity). The live-cell protease 
activity which is restricted to intact viable cells was measured using a fluorogenic, cell-permeant, 
peptide substrate (glycyl-phenylalanylaminofluorocoumarin, GF-AFC). This substrate enters intact 
cells, where it is cleaved by the live-cell protease activity to release AFC and generate a fluorescent 
signal that is proportional to the number of living cells. For this assay, 50 μL of the GF-AFC 
reagent was added to each well of a white-walled plate including ~5000 cells followed by mixing 
and incubation for one hour at 37oC. The live-cell fluorescence was measured at 
~400nmEx/~505nmEm on a GloMax®-Multi Microplate Multimode Reader (Promega AG, 
Dübendorf, Switzerland).  
A second, luminogenic cell-impermeant peptide substrate (alanyl-alanyl-phenylalanyl-
aminoluciferin; AAF-Glo™ Substrate) was used to measure dead-cell protease activity, which is 
released from cells that have lost membrane integrity. The AAF-Glo™ Substrate is not cell-
permeant; therefore, essentially no signal is generated from this substrate by intact, viable cells. 
Briefly, 50 μL of AAF-Glo™ reagent was added to each well from viability assay followed by 
orbital shaking, and incubate for 15 minutes at room temperature. The dead-cell fluorescence was 
measured at ~400nmEx/~505nmEm. Each sample was matured in triplex format and data were 
collected as relative fluorescence units (RFU). 
 
Quantification of caspase-3 and caspase-7 activities  
The caspases-3 and -7 activities were measured using the Caspase-Glo®3/7 Assay kit (Promega 
AG, Dübendorf, Switzerland) according to the manufacturer´s instructions. This kit is based on the 
cleavage of the amino acid sequence DEVD of a luminogenic substrate by the caspases-3 and -7 
which results in a luminescent signal. For this assay 50 μL of freshly prepared Caspase-Glo Reagent 
was added to each well of a white-walled plate including ~5000 cells followed by two hours 
incubation at room temperature. Luminescence was measured at ~485nmEx/~527nmEm on a 
GloMax®-Multi Microplate Multimode Reader (Promega AG, Dübendorf, Switzerland). Each 
sample was matured in triplex format and data were collected as relative fluorescence units (RFU). 
 
Simultaneous isolation of DNA, RNA miRNA and proteins 
The selected cell lines (MDA-MB231, SKBR3 and HB2) were subject for simultaneous DNA, 
RNA, miRNA and proteins isolation (5×106 cells per sample) before treatment, after treatment and 
at five point follow-ups (1st, 3rd, 5th, 7th and 10th passages) using AllPrep® DNA/RNA/Protein Mini 
Kit (QIAGEN AG, Basel, Switzerland) according to the published protocol [1]. The RNeasy 
MinElute Cleanup Kit (QIAGEN AG, Basel, Switzerland) was used for isolation and purification of 
enriched miRNAs. The quantity of extracted species was assessed using a NanoDrop ND-1000 
spectrophotometer (Biolab, Mulgrave, VIC, Australia). The extracted RNA samples were analyzed 
for the size fractionation using RNA 6000 Nano LabChip® as well as using RNA 6000 Pico 
LabChip® for the enriched miRNAs (Agilent Technologies, GmbH, Waldbronn, Germany). 
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Methylation quantification of candidate tumor suppressor genes (TSGs) using thymidine-specific 
cleavage mass array on MALDI-TOF silico-chip 
The EpiTYPER™ assay using matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) and MassCLEAVETM reagent was assessed for the quantification 
of DNA methylation patterns of four TSGs (BMP6, BRCA1, CST6, CDKN1A,  CDKN2A, P16-
INK4A and TIMP3) according to the previously published methods [2,3,4,5]. 
 
Bisulfite treatment. To perform bisulfite conversion of the target sequence, the Epitect® 
Bisulfite Kit (QIAGEN AG, Basel, Switzerland) was used.  
 
Primer designing and PCR-tagging for EpiTYPERTM assay. CpG density and CpG sites of 
target sequences in six TSGs were analyzed for the PCR primer design. We used previously 
designed and tagged primers (reverse primer with T7-promoter tag and forward primer with 10mer 
tag sequence as balance) for the candidate genes. The primer sequences are summarized in the table 
2. Selected amplicons were mostly located in the promoter regions, or started from the promoter 
and partially covered the first exon [3]. For the PCR on bisulfite-treated genomic DNA (gDNA), the 
following PCR conditions were used: 1x: 95°C for 10 min; 48x: 95°C for 30s, Ta for 40s, 72°C for 
1 min; 1x 72°C for 5 min. The PCR cocktail was: 2μL DNA (2.00μL of at least 10 ng/μL DNA for 
a final concentration of 2ng/μL per reaction) in a 10μL total volume using 10 pmol of each primer, 
200μM dNTP, 0.2 unit Hot Start Taq DNA polymerase, 1.5mM MgCl2 and the buffer supplied with 
the enzyme.  
 
In vitro transcription, T-cleavage assay and Mass spectrometry. In vitro transcription and 
T-cleavage were assessed according to the previously published methods [3,5,6]. Twenty-two 
nanoliters of cleavage reaction were robotically dispensed (nanodispenser) onto silicon chips 
preloaded with matrix (SpectroCHIP; SEQUENOM, San Diego). Mass spectra were collected using 
a MassARRAY Compact MALDI-TOF (SEQUENOM) and spectra’s methylation ratios were 
generated by the Epityper software v1.0 (SEQUENOM, San Diego).  
 
 
 
Table 2. The sequence of PCR tagged primers for in vitro transcription. 
 
Gene Primer Sequence (5’→3’) Length Ta 
Prodoct 
Size 
(bp) 
BMP6 
tag-EN1-FW AGGAAGAGAGGGGGTAAATTTTATGGTGGTTT 22+10 
57 397 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCCTTCCTAACCCTCAATCCTTA 22+31 
BRCA1 tag-EN1-FW 
AGGAAGAGAGAATTGGAGATTTTTATTAGG 20+10 56 413 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTAAATCTCAACRAACTCAC 18+31 
CST6 tag-EN1-FW 
AGGAAGAGAGGTTGGTAGTTTATTTTGGATAGTTT 25+10 59 445 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCAAATCCCRAAATTCTCC 18+31 
CDKN1A  tag-EN1-FW 
AGGAAGAGAGGGTAAATTTTTGTTTGTTAGAGTGG 25+10 60 419 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTTAACTTCRACAACTACTCACACCT 24+31 
CDKN2A 
tag-EN1-FW AGGAAGAGAGGGTTGTTTTTGGTAGGG 17+10 
58 580 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTATATAAACCACRAAAACCC 19+31 
P16-INK4A tag-EN1-FW 
AGGAAGAGAGTGGGGTTTTTATAATTAGGAAAGAATA 27+10 57 533 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCCACCCTCTAATAACCAACCAA 22+31 
TIMP3 tag-EN1-FW 
AGGAAGAGAGTTTTGTTATTGGTTTGAGGG 20+10 59 441 T7-EN1-RV CAGTAATACGACTCACTATAGGGAGAAGGCTCCAAACTCCAACTACCCA 18+31 
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Microarray analysis and qRT-PCR validations 
MRNA expression analysis. Microarray analyses of the mRNA samples at various follow-up 
passages including two independent biological replicates were conducted using the Affymetrix 
Genome 133 Plus 2.0 GeneChips (Affymetrix Inc., Santa Clara, U.S.). The synthesis of cDNA was 
carried out with a starting amount of approximately 50 ng total RNA using the NuGEN Ovation 
RNA Amplification System V2 (NuGEN Technologies Inc.; San Carlos, U.S.). The arrays were 
hybridized with the biotinlabeled fragments and rotated in the hybridization ovens for 18 hours at 
45°C and 60 rpm (miRNA arrays rotated 16 hours at 48°C. The arrays were washed and stained 
with a streptavidin phycoerythrin conjugate on GeneChip Fluidics 450 Workstations, and scanned 
on a GeneChip Scanner 3000 7G (Affymetrix Inc.) The expression data were acquired using the 
Affymetrix GeneChip Operating Software (GCOS). The systems were used to  
generate the numerical values of the probe intensity (Signal). The HGU133Plus2 annotations  
(v2.1.0, ENTREZG) supplied by University of Michigan was used as probe identifier 
(http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/12.1.0/entrezg.asp). 
 
 
MicroRNA expression analysis. Microarray analyses of the enriched miRNAs samples at 
various follow-up passages were carried out using Affymetrix GeneChipR miRNA array (v1.0). 
The labeling of the microRNAs was carried out with a starting amount of approximately 100 ng 
small RNA using the FlashTag Biotin HSR RNA Labeling Kit (Genisphere). The labeling process 
was performed in two stages (i) Poly (A) Tailing (ii) FlashTag Biotin HSR Ligation. The expression 
data were acquired using the Affymetrix GeneChip Command Console Software (AGCC). The 
miRNA-1_0 annotations (20081203) supplied by Affymetrix was used as probe identifier. 
 
Data analysis. After log transformation and Robust Multi-array Analysis (RMA) 
normalization, differentially expressed mRNAs/miRNAs were defined by applying three filtering 
criteria (mean intensity greater than six, fold change greater than two and ANOVA set to P<0.05) 
using Partek Genomics Suite software v6.5 (Partek Incorporated, Missouri, USA). MiRNAs that 
were differentially expressed between untreated and treated or follow-up passages were identified 
using a paired t–test at P<0.05 significance. Present study reported differentially expressed mature 
miRNAs. Unsupervised hierarchical clustering of significant up- and down-regulated 
genes/miRNAs were applied using Partek software with standard Pearson’s correlation as similarity 
measurement, and Ward’d method for clustering the data. 
 
qRT-PCR validation. To confirm the microarray findings, quantitative real-time (qRT) PCR 
was used for several candidate mRNAs and miRNAs (Table 3 and 4). For each cell line, RNA used 
for microarray analysis was also used to synthesize cDNA with High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, USA). Real-time primers were then designed for each gene 
using Primerquest Software (Integrated DNA Technologies). For qRT-PCR analysis, synthesized 
cDNAs amplified with specific gene primers using SYBR® Green 2X PCR Master Mix (Applied 
Biosystems). In order to analyze miRNAs with qRT-PCR the miScript PCR system kit was used 
with the commercially available primers for mature miRNAs (QIAGEN AG, Basel, Switzerland). 
Raw values were normalized using geometric mean of seven reference genes (18S, GAPDH, GRB2, 
Hmox2, TMEM184B, USP7 and ZNF398) for mRNA expression and two reference miRNAs (miR-
151 and miR-193a) for miRNA expression as internal controls. These reference genes/miRNAs 
were selected according to their low variability overall microarray data in all the analyzed samples 
[7,8,9,10]. Real-time PCR reactions were performed in two replicates and including no-template 
controls using ABI Prism 7000 Sequence Detection System (Applied Biosystems). The fold 
difference for each sample was calculated using the comparative Ct method [11]. 
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Table 3. The primer sequence of the selected mRNAs for qRT-PCR. 
 
Gene Name Ensembl Gene ID Primer Sequence (5’→3’) Length (bp) Ta 
Prodoct 
Size (bp) 
18S* ENST00000445125 FW CGCCGCTAGAGGTGAAATTCT 21 60.1 66 RV CATTCTTGGCAAATGCTTTCG 21 
BRCA1 ENST00000357654 FW AGTTGGTCTGAGTGACAAGG 20 60.7 109 RV CTGCTTCACCTAAGTTTGAATCC 23 
CDKN1A 
(P21) ENST00000244741 
FW TGCGTTCACAGGTGTTTCTG 20 60.3 217 RV GTCACCCTCCAGTGGTGTCT 20 
P16-INK4A ENST00000304494 FW GAGGAAGAAAGAGGAGGG 17 59.5 265 RV CATCATGACCTGGATCGG 18 
CST6 ENST00000312134 FW CTACTTCCGAGACACGCACA 20 59.8 201 RV GGAACCACAAGGACCTCAAA 20 
CXCR4 ENST00000241393 FW CCAGAAACTTCAGTTTGTTGG 21 60.79 242 RV ATGATGGAGTAGATGGTGGG 20 
DNMT1 ENST00000340748 FW CTGGCTTTGAGAGTTATGAGG 21 60.4 182 RV CATTAACACCACCTTCAAGAG 21 
DNMT3A ENST00000264709 FW GATGATTGATGCCAAAGAAGTG 22 60.2 272 RV CCAAATACCCTTTCCATTTCAG 22 
DNMT3B ENST00000328111 FW CAAGGAAATACGAGAACAAGAC 22 59.3 195 RV GACAAACAGCCATCTTCCAG 20 
ERBB2 ENST00000269571 FW GCCTGTCCCTACAACTACC 19 61 178 RV GTAACTGCCCTCACCTCTC 19 
ESR1 ENST00000206249 FW CAGACACTTTGATCCACCTG 20 60.63 115 RV GCCTTTGTTACTCATGTGCC 20 
ESR2 ENST00000341099 FW GGATGGAGGTGTTAATGATGG 21 60.53 233 RV GAGGGTACATACTGGAATTGAG 22 
ETS1 ENST00000319397 FW TCACTAAAGAACAGCAACGAC 21 60.2 250 RV TGGTTTCACATCCTCTTTCTG 21 
GAPDH* ENST00000229239 FW GAAGGTGAAGGTCGGAGT 18 60 226 RV GAAGATGGTGATGGGATTTC 20 
GJA1 (CX43) ENST00000282561 FW AGGAAAGTACCAAACAGCAG 20 60.2 209 RV CAGTTGAGTAGGCTTGAACC 20 
GRB2* ENST00000316804 FW AGAAATGAAACCACATCCGT 20 60.3 155 RV ACATCGTTTCCAAACTTGACAG 22 
Hmox2* ENST00000219700 FW AACCAAATGAGAATGGCTGAC 21 61.2 164 RV GGCTGAGTATGTGAAGTAAAGTG 23 
IL6 ENST00000404625 FW CACTCACCTCTTCAGAACGA 20 61.08 196 RV GCAAGTCTCCTCATTGAATCC 21 
MERTK ENST00000295408 FW TCAACATCAAAGCAATTCCCTC 22 61.05 205 RV GATTTGGTACAGATGTGGTAAGG 23 
MYC ENST00000377970 FW GATTCTCTGCTCTCCTCGAC 20 61.17 110 RV TTCTTGTTCCTCCTCAGAGTC 21 
PDCD4 ENST00000280154 FW GAAGTTGCGGAAATGTTAAGAG 22 60.17 259 RV ACAGCTCTAGCAATAAACTGG 21 
PGR ENST00000263463 FW CAATGGAAGGGCAGCAC 17 60.58 231 RV CCACTGACGTGTTTGTAGG 19 
PTEN ENST00000371953 FW CGGAACTTGCAATCCTCAG 19 60.8 233 RV GTTTCCTCTGGTCCTGGT 19 
RASSF1 ENST00000359365 FW AAGTTCACCTGCCACTACC 19 60.4 217 RV CCGTCCTTGTTCAAGCTC 18 
TMEM184B* ENST00000361906 FW CACCAGATCTACATGCACCT 20 61.3 `277 RV TACATACAGCTGGACTCAATGG 22
USP7* ENST00000344836 FW ATTCCTAACATTGCCACCAG 20 60.1 256 RV ATTTACACCATTTGCCATCC 20 
VEGFA ENST00000372067 FW GAGTACCCTGATGAGATCGAG 21 60.05 213 RV CTTTCTTTGGTCTGCATTCAC 21 
ZNF398* ENST00000420008 FW CAGGTATTAAGGGAGATATCCCA 23 60.2 161 RV TAGCATAATCCATGGAGATGAG 22 
 
* selected as reference gene 
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Table 4. The primer sequence and ID of validated miRNAs by qRT-PCR. 
 
MIR ID Sanger ID Sanger Accession Sequence 5‘  3‘ 
hsa-mir-125b-1 hsa-miR-125b MIMAT0000423 UCCCUGAGACCCUAACUUGUGA 
hsa-mir-130a hsa-miR-130a MIMAT0000425 CAGUGCAAUGUUAAAAGGGCAU
hsa-mir-151** hsa-miR-151-3p MIMAT0000757 CUAGACUGAAGCUCCUUGAGG 
hsa-mir-152 hsa-mir-152 MIMAT0000438 UCAGUGCAUGACAGAACUUGG 
hsa-mir-181a hsa-miR-181a MIMAT0000256 AACAUUCAACGCUGUCGGUGAGU
hsa-mir-183 hsa-mir-183 MIMAT0000261 UAUGGCACUGGUAGAAUUCACU 
hsa-mir-193a** hsa-miR-193a-5p MIMAT0004614 UGGGUCUUUGCGGGCGAGAUGA 
hsa-miR-21_2 hsa-miR-21 MIMAT0000076 UAGCUUAUCAGACUGAUGUUGA
hsa-miR-24_1 hsa-miR-24 MIMAT0000080 UGGCUCAGUUCAGCAGGAACAG 
hsa-mir-27a hsa-miR-27a MIMAT0000084 UUCACAGUGGCUAAGUUCCGC 
hsa-mir-27b hsa-miR-27b MIMAT0000419 UUCACAGUGGCUAAGUUCUGC
hsa-miR-29b_1 hsa-miR-29b MIMAT0000100 UAGCACCAUUUGAAAUCAGUGUU 
hsa-mir-378 hsa-miR-378 MIMAT0000732 ACUGGACUUGGAGUCAGAAGG 
hsa-mir-455 hsa-miR-455-3p MIMAT0004784 GCAGUCCAUGGGCAUAUACAC
hsa-miR-99a_1 hsa-miR-99a MIMAT0000097 AACCCGUAGAUCCGAUCUUGUG 
 
** selected as reference miRNAs 
 
Mutation screening of P16-INK4A gene 
Full gene sequencing of P16-INK4A has been performed on the promoter region, 5’UTR, three 
exons including exon/intron boundaries (exon 1-3) and 3’UTR. Information of primer sequences are 
listed  
in Table 5. The PCR for each region carried out in a 50 μL total volume containing 100ng DNA, 
200μM of each dNTP, 20 pmoL of each primer, 2.5 U Hot Start Taq DNA polymerase, 1X PCR 
buffer and 1.5 mM MgCl2. The PCR was performed in 40 cycles under following condition: 
denaturation at 94°C for 15 sec, annealing step for 15 sec at appropriate Ta that is mentioned in 
Table 5, and 60 sec primer extension at 72°C. Direct DNA sequencing was performed using a Big 
Dye terminator v3.1 cycle sequencing kit and automated sequencer was performed (ABI 3130, 
Applied Biosystem). The results of DNA sequence analysis were compared with the reference 
sequences of the gene bank (www.ncbi.nlm.mih.gov/nucleotide) using DNASTAR sequence 
alignment software (DNASTAR Lasergene 8, Inc., Madison, USA). All sequencing reactions were 
performed in both directions and confirmed for concordance.  
 
Table 5. The primer sequence for full P16-INK4A gene sequencing. 
 
Gene Name Primer Sequence (5’→3’) Length (bp) Ta 
Prodoct 
Size (bp) 
P16-INK4A 
(Promoter) 
FW GCTCCTGAAAATCAAGGGTTG 21 
58 648 
RV CCTGCTCTCCCCCTCTCC 18 
P16-INK4A  
(5’UTR + Exon1) 
FW AGTCCTCCTTCCTTGCCAAC 20 57 620 RV CTTCTGAAAACTCCCCAGGA 20 
P16-INK4A  
(Exon2) 
FW AATTAGACACCTGGGGCTTG 20 57 582 RV AGGGCGATAGGGAGACTCAG 20 
P16-INK4A  
(Exon3 + 3’UTR) 
FW GTAGGGACGGCAAGAGAGG 19 57 660 RV TGAAACAACAGTGTCAGAAACG 22 
 
 
Proteomic profiling 
Protein pallets from AllPrep® extraction (5 x 106 cells per sample) were directly solubilized in a 
buffer consisting 7M urea, 2M thiourea, 4% CHAPS, 20mM DTT and 2% ampholines, pH 3-10 
(Invitrogen) for a total volume of 0.1mL.  
Two-dimensional gel electrophoresis (2DE) and spot visualization the first dimension was 
run using the ISODALT system (ampholines pH 3-10 (Invitrogen)) [12,13]; and for the second 
dimension 11-19% linear acrylamide gradient was used. Protein spots were visualized by silver 
staining and wet silver-stained gels were scanned by Pharmacia Image Scanner with 300 dpi, 16 bit 
based on published method [1].  
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Image analysis and spot quantification. Each protein sample was run by 2DE in triplicate in 
order to evaluate gel reproducibility and improve the reliability of the qualitative and qualitative 
changes in protein expression measurement by means of electrophoresis. Progenesis SameSpot 
software (v 4.0, NonLinear Dynamics, UK) was used for gel alignment, spot detection, spot 
quantification, and normalization for the total spot volume in each gel, and the data were 
statistically analyzed using the incorporated statistical package. Gel images were automatically 
aligned after manually assigning 20 landmark vectors. The samples variables were expressed as 
mean of each replicate (SE or percentages, and were statistically analyzed by ANOVA). The cutoff 
level for a differentially expressed protein was defined based on an ANOVA at significance of 
P<0.05 using the SameSpots software considering a minimum of 1.5-fold change (normalized 
volume). In addition, we applied separate non-parametric statistical analyses between each pair of 
samples including untreated vs. treated and other follow-up passages. 
 
Liquid Chromatography - Mass Spectrometry and Liquid Chromatography - Tandem Mass 
Spectrometry (LC-MS-MS) 
The protein spots of interest were manually excised from the gels and underwent in-gel 
digestion with trypsin. The trypsin digested proteins were analyzed by capillary liquid 
chromatography tandem MS (LC-MS-MS) using a setup of a ProteoCol trap C-18 column (0.15 x 
10mm, 3 m particle size, 300Å) (SGE Analytical Science, Victoria, AU) and a separating column 
(0.1mm x10cm) that had been packed with Magic 300Å C18 reverse-phase material (5 mm particle 
size, Swiss Bioanalytics, Birsfelden, Switzerland). The columns were connected on line to an 
Orbitrap FT hybrid instrument (Thermo Finnigan, San Jose, CA, USA). The solvents used for 
peptide separation consisted 0.1% acetic acid in water (solvent A) and 0.1% acetic acid and 80% 
acetonitrile in water (solvent B). Peptides were injected via a 2 L loop onto the trap column with 
the capillary pump of an Agilent 1200 system set to 5 L/min. After 15 min, the trap column was 
switched into the flow path of the separating column. A linear gradient from 2 to 35% solvent B in 
solvent A in 60 min was delivered with an Agilent 1200 nano pump at a flow rate of 500 nL/min. 
After 60 min the percentage of solvent B was increased to 60% in ten minutes and further increased 
to 80% in 2 min. The eluting peptides were ionized at 1.7 kV. The mass spectrometer was operated 
in a data-dependent fashion. The precursor scan was done in the Orbitrap set to 60,000 resolutions, 
while the fragment ions were mass analyzed in the LTQ instrument. A top five method was run so 
that the five most intense precursors were selected for fragmentation. 
  
Peptide identification. The MS-MS spectra were then searched against the human data bank 
(NCBI non-redundant, version October 1st, 2010) using TurboSequest software [14]. The data bank 
was searched with 10 ppm precursor ion tolerance, while the fragment ions were set to 0.5 Da 
tolerances. Cleavage rules were set to fully enzymatic – cleaves at both ends, allowing 2 missed 
cleavages. Post filtering was set to the following parameters: CN, 0.1; Xcorr versus charge state 
was 1.50 (1+), 2.00 (2+), 2.50 (3+); peptide probability, 0.01; protein probability 0.01. Valid 
identification required two or more peptides independently matching the same protein sequence, a 
significant peptide score (P<0.05), and the manual confirmation of agreement between the spectra 
and peptide sequence. At least two peptides were required for protein identification. Protein 
quantification and data validation was performed using Scaffold (version Scaffold 3.00.06; 
Proteome Software, Portland, OR, USA), which models the score distributions of the entire dataset 
of spectra. Database search files generated by TurboSequest were imported into Scaffold and 
analyzed using the tandem searches against the same protein sequence database the same search 
parameters as the associated TurboSequest search.  
 
Gene ontology Enrichment  
The gene ontology (GO) enrichment was assessed using Partek Genomics Suite software v6.5 
(Partek Incorporated, Missouri, USA), which could take a list of significantly expressed genes and 
see how they group in the functional hierarchy. The enrichment score were calculated using a chi-
square test comparing the proportion of the gene list in a group to the proportion of the background 
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in the group. If a functional group had an enrichment score over 1, the functional category was over 
expressed. A value of 3 or higher corresponds to significant over expression (P<0.05). 
 
In silico prediction of miRNA targets 
Conserved and non-conserved targets of detected miRNAs were identified using TargetScan 
5.1 (http://www.targetscan.org/). List of predicted targets was obtained from TargetScan data 
download and further investigated using pathway analysis. For important miRNAs, the mRNA 
targets were validated to find exact miRNA complementary sites using RNA22 program 
(http://cbcsrv.watson.ibm.com/rna22.html). The default stringency settings were used: maximum 
number of allowed UN-base paired bases =0 in seed/nucleus of 7 nucleotides, and minimum 
number of paired-up bases in heteroduplex = 14; maximum folding energy for heteroduplex 
(Kcal/mol =225). 
 
Cell signaling and pathway analysis 
Gene networks and canonical pathways representing key genes, miRNAs and proteins were 
identified using the Pathway Studio® software version 7 and ResNet® 7 (Mammal) database 
(Ariadne Genomics, Inc., Rockville, USA). The data set containing gene/miRNA identifiers and 
corresponding fold changes were uploaded into the Pathway Studio and each gene identifier was 
mapped to its corresponding gene object. The functional analysis identified the biological functions 
and/or diseases that were most relevant to the data sets and facilitated the understanding beyond 
their functional link to breast neoplasm. This analysis provided an approach to compare different 
kinds of cellular interactions, including protein-protein interactions as well as genes-miRNAs 
interactions. 
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Supplementary Data 2 
MRNA Expression Profiles 
 
 
 
Fig. 1. PCA analysis of three different studied cell lines (HB2, MDA-MB231 and SKBR3).  
 
 
 
 
 
 
Fig. 2. a) Comparison of significant up- and down-regulated union genes within three analyzed cell 
lines. b) Comparison of significant up- and down-regulated intersect genes within three analyzed cell 
lines. 
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Fig. 3. a) Gene set analysis and GO enrichment score for union genes of three analyzed cell lines. A value 
of 3 or higher corresponds to significant over expression (chi-square test; P<0.05). b) Forest plot analysis 
shows up- and down-regulated of HB2 union genes based on their ontology enrichment. c) Forest plot 
analysis of MDA-MB231 union genes. d) Forest plot analysis of SKBR3 union genes.  
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Gene Expression Profiles of HB2  
(Breast Epithelial Cell Line) 
 
 
 
 
Fig. 4. The number of significant up- and down-regulated genes within different passages of HB2. 
 
 
 
 
 
Fig. 5. Heatmap shows significant up- and down-regulated 17 intersect genes of HB2. 
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Fig. 6. Heatmap shows significant up- and down-regulated 14 oncogenes out of 991 union genes in 
HB2. 
 
 
 
 
Fig. 7. Pathway analysis of 10 out of 14 oncogenes (ETS1, RAB1S, CXCL1, CXCL2, MAFF, LCN2, 
PDGFB, ETV7, RAB33B and MAP3K8) that are linked to breast neoplasms and metastasis. These 
genes are shown as significant up- and down-regulated during the different passages of HB2. 
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Fig. 8. Heatmap shows significant up- and down-regulated five tumor suppressor genes out of 991 
union genes in HB2. 
 
 
 
 
Fig. 9. Pathway analysis of three out of five tumor suppressor genes (FAT3, PTEN and DLGAP5) that are 
linked to breast neoplasms and metastasis. These are significant up- and down-regulated genes during the 
different passages of HB2. 
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Fig. 10. Expression level of six cancer related genes after treatment using qPCR. Four genes 
(CDKN1A, VEGFR, IL6 and GJA1) as intersection genes in the three analyzed cell lines, ETS1 and 
PTEN as examples of significantly changed oncogenes and tumor suppressor genes respectively. 
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Gene Expression Profiles of MDA-MB231  
(Highly Aggressive Breast Cancer Cell Line) 
 
 
 
 
Fig. 11. The number of significant up- and down-regulated genes within different passages of 
MDA-MB231. 
 
 
 
 
 
Fig. 12. Heatmap shows significant up- and down-regulated 61 intersect genes of MDA-MB231. 
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Fig. 13. Heatmap shows significant up- and down-regulated six oncogenes out of 431 union genes in  
MDA-MB231. 
 
 
 
 
Fig. 14. Pathway analysis of five out of six oncogenes (MERTK, RAB31, CXCL1, CXCL2 and 
LCN2) that are linked to breast neoplasms and metastasis. These genes are shown as significant up- 
and down-regulated during the different passages of MDA-MB231. 
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Fig. 15. Heatmap shows significant up- and down-regulated tumor suppressor gene out of 431 
union genes  
in MDA-MB231. 
 
 
 
 
 
 
 
Fig. 16. Pathway analysis of CST6 tumor suppressor gene that are linked to breast neoplasms and 
metastasis. This gene is marked as significant up- and down-regulated during the different passages 
of MDA-MB231. 
159 Radpour et al. Research Article 
 
 
 
 
 
Fig. 17. Expression level of six cancer related genes after treatment using qPCR. Four genes 
(CDKN1A, VEGFR, IL6 and GJA1) as intersection genes in the three analyzed cell lines, MERTK 
and CST6 as examples of significantly changed oncogenes and tumor suppressor genes respectively. 
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Gene Expression Profiles of SKBR3  
(Non-aggressive Breast Cancer Cell Line) 
 
 
 
Fig. 18. The number of significant up- and down-regulated genes within different passages of 
SKBR3. 
 
 
 
 
Fig. 19. Heatmap shows significant up- and down-regulated 228 intersect genes of SKBR3. 
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Fig. 20. Heatmap shows significant up- and down-regulated 37 oncogenes out of 2406 union genes 
in SKBR3. 
 
 
 
 
Fig. 21. Pathway analysis of six out of 37 oncogenes (CXCL2, CXCL3, ERBB2, VAV1, MYC, 
BRAF, KLF6 and LCN2) that are linked to breast neoplasms and metastasis. These genes are shown 
as significant up- and down-regulated during the different passages of SKBR3. 
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Fig. 22. Heatmap shows significant up- and down-regulated 14 tumor suppressor genes out of 2406 
union genes in SKBR3. 
 
 
 
 
Fig. 23. Pathway analysis of seven out of 14 tumor suppressor genes (BRCA1, CDKN1B, STEAP3, 
ING4, RASSF1, CADM1 and FLCN) that are linked to breast neoplasms and metastasis. These genes are 
shown as significant up- and down-regulated during the different passages of SKBR3. 
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Fig. 24. Expression level of eight cancer related genes after treatment using qPCR. Four genes 
(CDKN1A, VEGFR, IL6 and GJA1) as intersection genes in the three analyzed cell lines, MYC and 
ERBB2 as examples of significantly changed oncogenes, BRCA1 and RASSF1 as an example of 
tumor suppressor genes. 
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Supplementary Data 3 
 
MicroRNA Expression Profiles 
 
 
 
 
 
 
 
 
Fig. 1. PCA analysis of three different studied cell lines (HB2, MDA-MB231 and SKBR3).  
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MicroRNA Expression Profiles of HB2  
(Breast Epithelial Cell Line) 
 
 
 
 
Fig. 2. The number of significant up- and down-regulated miRNAs within different passages of 
HB2. 
 
 
 
 
 
Fig. 3. Pathway analysis of one miRNAs out of three intersect miRNAs in HB2 that is linked to 
neoplasms, metastasis or carcinogenesis. 
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Fig. 4. Pathway analysis of 23 union miRNAs in HB2 that are linked to neoplasms, metastasis or 
carcinogenesis. 
 
 
 
 
 
Fig. 5. Heatmap shows significant up- and down-regulated 23 selected union miRNAs in HB2. 
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MicroRNA Expression Profiles of MDA-MB231  
(Highly Aggressive Breast Cancer Cell Line) 
 
 
 
 
Fig. 6. The number of significant up- and down-regulated miRNAs within different passages of 
MDA-MB231. 
 
 
 
 
 
 
Fig. 7. Pathway analysis of one intersect miRNAs in MDA-MB231 that is linked to neoplasms, metastasis 
or carcinogenesis. 
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Fig. 8. Pathway analysis of 30 union miRNAs in MDA-MB231 that are linked to neoplasms, metastasis or 
carcinogenesis. 
 
 
 
 
Fig. 9. Heatmap shows significant up- and down-regulated 30 selected union miRNAs in MDA-MB231. 
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MicroRNA Expression Profiles of SKBR3  
(Non-aggressive Breast Cancer Cell Line) 
 
 
 
 
Fig. 10. The number of significant up- and down-regulated miRNAs within different passages of 
SKBR3. 
 
 
 
 
 
Fig. 11. Pathway analysis of five miRNAs out of nine intersect miRNAs in SKBR3 that are linked to 
neoplasms,  
metastasis or carcinogenesis. 
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Fig. 12. Pathway analysis of 27 union miRNAs in SKBR3 that are linked to neoplasms, metastasis or 
carcinogenesis. 
 
 
 
 
Fig. 13. Heatmap shows significant up- and down-regulated 27 selected union miRNAs in SKBR3. 
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Fig. 14. Expression level of important cancer related miRNAs using qPCR.  
a) HB2 cell line. b) MDA-MB231 cell line. c) SKBR3 cell line. 
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Supplementary Data 4 
Proteomics Profiles  
 
HB2 (Breast Epithelial Cell Line) 
 
 
 
 
Spot picking gel for significant up- and down-regulated intersect proteins. 
Spot No. Anova (p) Fold change pI 
1373 0.022 4.9 5.07 
850 0.040 2.0 5.3 
1044 0.044 1.6 7.75 
1385 0.050 2.4 6.94
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MDA-MB231 (Highly Aggressive Breast Cancer Cell Line) 
 
 
 
 
 
 
Spot picking gel for significant up- and down-regulated intersect proteins. 
 
Spot No. Anova (p) Fold change pI 
1622 0.007 2.8 8.36
953 0.030 1.6 7.98
1486 0.032 1.9 8.7 
1492 0.036 2.0 8.46
1627 0.038 2.6 8.83
1536 0.038 1.6 3.72
1293 0.041 1.7 6.94
1076 0.047 1.9 8.47
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SKBR3 (Non- aggressive Breast Cancer Cell Line) 
 
 
 
 
 
 
Spot picking gel for significant up- and down-regulated intersect proteins. 
Spots No. Anova (p) Fold change pI 
710 0.005 3.1 7.2 
1543 0.013 2.2 6.11
2162 0.016 2.6 6.42
1727 0.016 1.9 8.24
603 0.017 7.3 7.76
1470 0.021 6.6 4.67
1121 0.025 3.2 5.87
854 0.030 1.9 8.16
1633 0.030 2.9 7.18
960 0.038 2.7 6.8 
1219 0.041 2.2 6.47
1234 0.045 2.0 8.78
605 0.047 3.3 7.7 
1590 0.047 2.5 6.53
1481 0.048 2.7 6.53
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Pathway analysis of 28 out of 41 detected proteins/ isoforms in the three analyzed cell lines (HB2, 
MDA-MB231, SKBR3) that are linked to neoplasms, metastasis or carcinogenesis. 
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Expression profiles of five genes/proteins that were detected similarly in both transcriptomic and 
proteomic analysis. A) Expression profiles of five differentially expressed genes in transcriptomic 
analysis. B-D) Expression profiles of five proteins as significant changing markers in proteomic 
analysis for the HB2, MDA-MB231 and SKBR3 cell lines. b1-2) Proteomic profile of Rangp1 
protein including expression pattern and LC/MS/MS detection. c1-2) Proteomic profile of Cnn2 
protein including expression pattern and LC/MS/MS detection. c3-5) Proteomic profiles of Sod2 
and Pebp1 proteins including expression pattern and LC/MS/MS detection. d1-2) Proteomic profile 
of Rnc3 protein including expression pattern and LC/MS/MS detection. 
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10. Summary and final conclusion 
The research for biomarker discovery for the diagnosis and prognosis of cancer patients has 
been going on for decades, yielding only a few major breakthroughs. Our increasing understanding 
of cancer biology, including genetic, molecular and cellular mechanisms, and epigenetic 
background is now providing objectives for the early detection of some malignancies including 
breast cancer. Such a progress has a direct impact on current activities dedicated to the search for 
sensitive and specific biomarkers for the early detection and diagnosis of cancers.  
In the present study, to find an efficient and high-throughput method for analyzing the 
methylation profile in breast cancer, we developed a method that allows for the simultaneous 
detection of multiple targets CpG residue by employing thymidine-specific cleavage on MALDI-
TOF MS. In this study, the large-scale analysis was the first high-throughput implementation of the 
method for quantification of methylation in breast cancer. We were able to conclude that T-specific 
assay in combination with MALDI-TOF MS is a sensitive and accurate technique for high-
throughput methylation analysis.  
Using the optimized method on MALDI-TOF silico-chips, we determined quantitative 
methylation changes of 22 candidate genes in breast cancer tissues. Firstly, we analyzed the 
methylation status of a total of 42,528 CpG dinucleotides on 22 genes in 96 different paraffin-
embedded tissues (48 breast cancerous tissues and 48 paired normal tissues). A two-way 
hierarchical cluster analysis was used to classify methylation profiles. In this study, 10 
hypermethylated genes (APC, BIN1, BMP6, BRCA1, CST6, ESRb, GSTP1, P16, P21 and TIMP3) 
were identified to distinguish between cancerous and normal tissues according to the extent of 
methylation. Individual assessment of the methylation status for each CpG dinucleotide indicated 
that cytosine hypermethylation in the cancerous tissue samples was mostly located near the 
consensus sequences of the transcription factor binding sites. These hypermethylated genes may 
serve as biomarkers for clinical molecular diagnosis and targeted treatments of patients with breast 
cancer.  
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To achieve a gene panel for developing a breast cancer blood-based test according to the 
pathologic methylation changes, we quantitatively assessed the DNA methylation proportion of 248 
CpG sites per sample (total of 31,248 sites in all analyzed samples) on 10 candidate genes (APC, 
BIN1, BMP6, BRCA1, CST6, ESR-b, GSTP1, P16, P21 and TIMP3). The number of 126 samples 
consisting of two different cohorts was used (first cohort: plasma samples from breast cancer 
patients and normal controls; second cohort: triple matched samples including cancerous tissue, 
matched normal tissue and serum samples). Circulating cell free methylated DNA of the 8 tumor 
suppressor genes (TSGs) was significantly higher in patients with breast cancer compared to normal 
controls. Using eight genes as a panel to develop a blood-based test for breast cancer, a sensitivity 
and specificity of more than 90% could be achieved in distinguishing between tumor and normal 
samples. Presented data is promising to design a gene panel and develop a blood-based screening 
method for breast cancer which relies on pathologic methylation changes. Tissue specific and 
blood-based methylation markers might provide valuable information as diagnostic and predictive 
markers for breast cancer, as well as for developing novel targeted therapeutic strategies.  
Analyzing the relative telomere length in paired breast cancer and matched normal tissue 
demonstrated a significant shortening of tumor telomere regions compared to paired adjacent 
normal tissues. Similarly, telomere lengths were significantly shorter in advanced stage cases, and 
in those with higher histological grades. In conclusion, our data suggests that shortened telomere 
length is significantly correlated with breast carcinogenesis. Moreover, promoter hypermethylation 
of the p16/Rb and p53/p21 pathways showed significant correlation with telomere shortening. The 
results suggested that inactivation of p16/Rb and/or p53/p21 pathways by hypermethylation may be 
linked to critical telomere shortening, leading to genome instability and ultimately to malignant 
transformation. Thus, shortened telomere length and hypermethylation of p53, p21 and p16 
promoters might serve as biomarkers in breast cancer. 
Epigenetic changes can be pharmacologically reversible and could be a useful target to develop 
new therapeutic strategies for cancer therapy. Reversal hypermethylation of silenced 
genes/miRNAs inhibiting malignant phenotypes is increasingly being targeted for cancer therapy 
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and prevention strategies. In our study, the therapeutic value of detected hypermethylated tumor 
suppressor genes in different subtypes of breast cancer was assessed after treatment with a 
demethylating agent (5-aza-2’-deoxycytidine; DAC). Additionally, we investigated 
multidimensional models to predict effects of DAC treatment at the level of the genome, epigenome 
and proteome-wide alterations in highly aggressive and non-aggressive subtypes of breast cancer. 
The results provided early and late effects of this treatment in 3-dimentional follow-up omics model 
as cancer and non-cancer specific changes that may correlate with particular steps in breast 
neoplasm including cell proliferations, cell/tissue invasion, oncogenesis, angiogenesis, apoptosis, 
neoplasm metastasis and senescence. Additionally, beside the activation of epigenetically 
suppressed TSGs, we also showed significant down-regulation of some miRNAs with oncogenic 
functions in breast cancer cell lines as well as up-regulation of some other miRNAs with tumor 
suppressor functions that highlights the usefulness potential of a miRNA-based therapy in breast 
cancer. Present approach is suggested to be extended for other human solid tumor malignancies, 
alone or in combination with other treatments such as enforced targeted therapies for miR-29b. 
Achieving successful therapy with DAC required the application of repetitive optimal-dose 
cycles with the regular intervals that may allow efficient incorporation of the drug into the newly 
synthesized DNA undergoing mitosis during each treatment. Moreover, the obtained results 
provided a rationale for developing therapeutic strategies based on reactivation of epigenetically 
silenced genes/miRNAs in breast cancer. 
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